<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Nature</journal-id>
        <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Nature</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0028-0836</issn>
        <issn pub-type="epub">1476-4687</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC3465532</article-id>
        <article-id pub-id-type="pmcid-ver">PMC3465532.1</article-id>
        <article-id pub-id-type="pmcaid">3465532</article-id>
        <article-id pub-id-type="pmcaiid">3465532</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS393293</article-id>
        <article-id pub-id-type="pmid">23000897</article-id>
        <article-id pub-id-type="doi">10.1038/nature11412</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS393293</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA393293</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Comprehensive molecular portraits of human breast tumors</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <collab>The Cancer Genome Atlas Network</collab>
          </contrib>
        </contrib-group>
        <author-notes>
          <corresp id="FN1">Address Correspondence to: Charles M. Perou, PhD, Lineberger Comprehensive Cancer Center, 450 West Drive, CB# 7295, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, <email>cperou@med.unc.edu</email></corresp>
        </author-notes>
        <pub-date pub-type="epub">
          <day>23</day>
          <month>9</month>
          <year>2012</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <day>4</day>
          <month>10</month>
          <year>2012</year>
        </pub-date>
        <volume>490</volume>
        <issue>7418</issue>
        <issue-id pub-id-type="pmc-issue-id">215006</issue-id>
        <fpage>61</fpage>
        <lpage>70</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>13</day>
              <month>07</month>
              <year>2012</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>04</day>
              <month>04</month>
              <year>2013</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>04</day>
              <month>04</month>
              <year>2013</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2025-04-10 18:25:48.050">
              <day>10</day>
              <month>04</month>
              <year>2025</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <license>
            <license-p>Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: 
<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms393293.pdf"/>
        <abstract>
          <title>Summary</title>
          <p id="P1">We analyzed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, mRNA arrays, microRNA sequencing and reverse phase protein arrays. Our ability to integrate information across platforms provided key insights into previously-defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity. Somatic mutations in only three genes (<italic toggle="yes">TP53</italic>, <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">GATA3</italic>) occurred at &gt; 10% incidence across all breast cancers; however, there were numerous subtype-associated and novel gene mutations including the enrichment of specific mutations in <italic toggle="yes">GATA3</italic>, <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">MAP3K1</italic> with the Luminal A subtype. We identified two novel protein expression-defined subgroups, possibly contributed by stromal/microenvironmental elements, and integrated analyses identified specific signaling pathways dominant in each molecular subtype including a HER2/p-HER2/HER1/p-HER1 signature within the HER2-Enriched expression subtype. Comparison of Basal-like breast tumors with high-grade Serous Ovarian tumors showed many molecular commonalities, suggesting a related etiology and similar therapeutic opportunities. The biologic finding of the four main breast cancer subtypes caused by different subsets of genetic and epigenetic abnormalities raises the hypothesis that much of the clinically observable plasticity and heterogeneity occurs within, and not across, these major biologic subtypes of breast cancer.</p>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec sec-type="intro" id="S2">
        <title>Introduction</title>
        <p id="P2">Breast cancer is one of the most common cancers with greater than 1,300,000 cases and 450,000 deaths each year world-wide. Clinically, this heterogeneous disease is categorized into three basic therapeutic groups. The Estrogen Receptor (ER) positive group are the most numerous and diverse, with several genomic tests to assist in predicting outcomes for ER+ patients receiving endocrine therapy<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup>. The <italic toggle="yes">HER2/ERBB2</italic> amplified group<sup><xref rid="R3" ref-type="bibr">3</xref></sup> is a great clinical success because of effective therapeutic targeting of <italic toggle="yes">HER2/ERBB2</italic>, which has led to intense efforts to characterize other DNA copy number aberrations<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup>. Triple Negative Breast Cancers (TNBC), also known as Basal-like breast cancers<sup><xref rid="R6" ref-type="bibr">6</xref></sup>, are a group with only chemotherapy options, and an increased incidence in patients with germline <italic toggle="yes">BRCA1</italic> mutations<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> or of African ancestry<sup><xref rid="R9" ref-type="bibr">9</xref></sup>.</p>
        <p id="P3">Most molecular studies of breast cancer have focused on just one or two high information content platforms, most frequently mRNA expression profiling or DNA copy number analysis, and more recently massively parallel sequencing<sup><xref rid="R10" ref-type="bibr">10</xref>–<xref rid="R12" ref-type="bibr">12</xref></sup>. Supervised clustering of mRNA expression data has reproducibly established that breast cancers encompass several distinct disease entities, often referred to as the intrinsic subtypes of breast cancer<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup>. The recent development of additional high information content assays focused on abnormalities in DNA methylation, microRNA expression and protein expression, provide further opportunities to more completely characterize the molecular architecture of breast cancer. In this study, a diverse set of breast tumors were assayed using six different technology platforms. Individual platform and integrated pathway analyses identified many subtype-specific mutations and copy number changes that identify therapeutically tractable genomic aberrations and other events driving tumor biology.</p>
      </sec>
      <sec id="S3">
        <title>Samples and clinical data</title>
        <p id="P4">Tumor and germline DNA samples were obtained from 825 patients. Different subsets of patients were assayed on each platform: 466 tumors from 463 patients had data available on five platforms including Agilent mRNA expression microarrays (n=547), Illumina Infinium DNA methylation chips (n=802), Affymetrix 6.0 SNP arrays (n=773), microRNA sequencing (n=697), and whole exome sequencing (n=507); in addition, 348 of the 466 samples also had Reverse Phase Protein Array (RPPA) data (n=403). Due to the short median overall follow up (17 months) and the small number of overall survival events (93/818), survival analyses will be presented in a later publication. Demographic and clinical characteristics are presented in <xref rid="SD1" ref-type="supplementary-material">Supplemental Table 1</xref>.</p>
      </sec>
      <sec id="S4">
        <title>Significantly mutated genes in breast cancer</title>
        <p id="P5">Overall, 510 tumors from 507 patients were subjected to whole exome sequencing, identifying 30,626 somatic mutations comprised of 28,319 point mutations, 4 dinucleotide mutations, and 2,302 indels (ranging from 1 to 53 nucleotides). The point mutations included 6,486 silent, 19,045 missense, 1,437 nonsense, 26 read-through, 506 splice-site mutations, and 819 mutations in RNA genes. Comparison to COSMIC and OMIM databases identified 619 mutations across 177 previously reported cancer genes. Of 19,045 missense mutations, 9,484 were predicted to have a high probability of being deleterious by Condel<sup><xref rid="R15" ref-type="bibr">15</xref></sup>. The MuSiC package (Dees <italic toggle="yes">et al.</italic>, submitted), which determines the significance of the observed mutation rate of each gene based on the background mutation rate, identified 35 <underline>S</underline>ignificantly <underline>M</underline>utated <underline>G</underline>enes/SMG (excluding LOC or ENSG genes) by at least two tests (Convolution and Likelihood Ratio tests) with FDR &lt; 5% (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table 2</xref>).</p>
        <p id="P6">In addition to identifying nearly all genes previously implicated in breast cancer (<italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">PTEN</italic>, <italic toggle="yes">AKT1</italic>, <italic toggle="yes">TP53</italic>, <italic toggle="yes">GATA3</italic>, <italic toggle="yes">CDH1</italic>, <italic toggle="yes">RB1</italic>, <italic toggle="yes">MLL3</italic>, <italic toggle="yes">MAP3K1</italic> and <italic toggle="yes">CDKN1B</italic>), a number of novel SMGs were identified including <italic toggle="yes">TBX3</italic>, <italic toggle="yes">RUNX1</italic>, <italic toggle="yes">CBFB, AFF2</italic>, <italic toggle="yes">PIK3R1, PTPN22, PTPRD, NF1, SF3B1</italic>, and <italic toggle="yes">CCND3. TBX3</italic>, which is mutated in Ulnar-Mammary Syndrome and involved in mammary gland development<sup><xref rid="R16" ref-type="bibr">16</xref></sup>, harbored 13 mutations (8 frame-shift indels, 1 in-frame deletion, 1 nonsense, and 3 missense), suggesting a loss of function. Additionally, 2 mutations were found in <italic toggle="yes">TBX4</italic> and 1 mutation in <italic toggle="yes">TBX5</italic>, which are genes involved in Holt-Oram Syndrome<sup><xref rid="R17" ref-type="bibr">17</xref></sup>. Two other transcription factors, <italic toggle="yes">CTCF</italic> and <italic toggle="yes">FOXA1</italic>, were at or near significance harboring 13 and 8 mutations, respectively. <italic toggle="yes">RUNX1</italic> and <italic toggle="yes">CBFB</italic>, both rearranged in Acute Myeloid Leukemia and interfering with hematopoietic differentiation, harbored 19 and 9 mutations, respectively. <italic toggle="yes">PIK3R1</italic> contained 14 mutations, most of which clustered in the PIK3CA interaction domain similar to previously identified mutations in glioma<sup><xref rid="R18" ref-type="bibr">18</xref></sup> and endometrial cancer<sup><xref rid="R19" ref-type="bibr">19</xref></sup>. We also observed a statistically significant exclusion pattern among <italic toggle="yes">PIK3R1</italic>, <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">PTEN</italic>, and <italic toggle="yes">AKT1</italic> mutations (P = 0.025). Mutation of splicing factor <italic toggle="yes">SF3B1</italic>, previously described in Myelodysplastic Syndromes<sup><xref rid="R20" ref-type="bibr">20</xref></sup> and Chronic Lymphocytic Leukemia<sup><xref rid="R21" ref-type="bibr">21</xref></sup>, was significant with 15 non-silent mutations, of which 4 were a recurrent K700E substitution. Two protein tyrosine phosphatases (<italic toggle="yes">PTPN22</italic> and <italic toggle="yes">PTPRD</italic>) were also significantly mutated; frequent deletion/mutation of <italic toggle="yes">PTPRD</italic> is observed in lung adenocarcinoma<sup><xref rid="R22" ref-type="bibr">22</xref></sup>.</p>
      </sec>
      <sec id="S5">
        <title>Association between mutations and mRNA-expression subtypes</title>
        <p id="P7">We analyzed the somatic mutation spectrum within the context of the four mRNA-expression subtypes, excluding the Normal-like group due to small numbers (n=8) (<xref rid="F1" ref-type="fig">Figure 1</xref>). Several SMGs showed mRNA-subtype (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figures 1–3</xref>) and clinical-subtype specific patterns of mutation (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table 2</xref>). SMGs were considerably more diverse and recurrent within Luminal A and Luminal B tumors than within Basal-like and HER2E subtypes; however, the overall mutation rate was lowest in Luminal A subtype and highest in the Basal-like and HER2E subtypes. The Luminal A subtype harbored the most SMGs, with the most frequent being <italic toggle="yes">PIK3CA</italic> (45%), followed by <italic toggle="yes">MAP3K1</italic>, <italic toggle="yes">GATA3</italic>, <italic toggle="yes">TP53</italic>, <italic toggle="yes">CDH1</italic>, and <italic toggle="yes">MAP2K4.</italic> 12% of Luminal A tumors contained likely inactivating mutations in <italic toggle="yes">MAP3K1</italic> and <italic toggle="yes">MAP2K4</italic>, which represent two contiguous steps in the p38/JNK1 stress kinase pathway<sup><xref rid="R23" ref-type="bibr">23</xref></sup>. Luminal B cancers exhibited a diversity of SMGs with <italic toggle="yes">TP53</italic> and <italic toggle="yes">PIK3CA</italic> (29% each) being the most frequent. The luminal tumor subtypes markedly contrasted with Basal-like cancers where <italic toggle="yes">TP53</italic> mutations occurred in 80% of cases and the majority of the Luminal SMG repertoire, except <italic toggle="yes">PIK3CA</italic> (9%), were absent or near absent. The HER2-Enriched subtype (HER2E), which has frequent <italic toggle="yes">HER2</italic>/<italic toggle="yes">ERBB2</italic> amplification (80%), had a hybrid pattern with a high frequency of <italic toggle="yes">TP53</italic> (72%) and <italic toggle="yes">PIK3CA</italic>(39%) mutations and a much lower frequency of other SMGs including <italic toggle="yes">PIK3R1</italic> (4%).</p>
        <p id="P8">Intrinsic mRNA-subtypes differed not only by mutation frequencies, but also by mutation type. Most notably, <italic toggle="yes">TP53</italic> mutations in Basal-like tumors were mostly nonsense and frame-shift, while missense mutations predominated in Luminal A and B tumors (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 1</xref>). 58 somatic <italic toggle="yes">GATA3</italic> mutations, some of which were previously described<sup><xref rid="R24" ref-type="bibr">24</xref></sup>, were detected including a hot spot 2bp deletion within intron 4 only in the Luminal A subtype (13/13 mutants) (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 2</xref>). In contrast, 7/9 frame-shift mutations in exon 5 (DNA binding domain) occurred in Luminal B cancers. <italic toggle="yes">PIK3CA</italic> mutation frequency and spectrum also varied by mRNA-subtype (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 3</xref>); the recurrent <italic toggle="yes">PIK3CA</italic> E545K mutation was present almost exclusively within Luminal A (25/27) tumors. <italic toggle="yes">CDH1</italic> mutations were common (30/36) within the lobular histologic subtype and corresponded with lower <italic toggle="yes">CDH1</italic> mRNA (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 4</xref>) and protein expression. Finally, we identified 4/8 somatic variants in <italic toggle="yes">HER2</italic>/<italic toggle="yes">ERBB2</italic> within lobular cancers, 3 of which were within the tyrosine kinase domain.</p>
        <p id="P9">We performed analyses on a selected set of genes<sup><xref rid="R25" ref-type="bibr">25</xref></sup> using the normal tissue DNA data and detected a number of germline predisposing variants. These analyses identified 47/507 patients with deleterious germline variants, representing nine different genes (<italic toggle="yes">ATM, BRCA1, BRCA2, BRIP1, CHEK2, NBN, PTEN, RAD51C,</italic> and <italic toggle="yes">TP53;</italic>
<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 3</xref>), supporting the hypothesis that ~10% of sporadic breast cancers may have a strong germline contribution. These data confirmed the association between the presence of germline <italic toggle="yes">BRCA1</italic> mutations and Basal-like breast cancers<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup>.</p>
      </sec>
      <sec id="S6">
        <title>Gene expression analyses (mRNA and microRNA)</title>
        <p id="P10">Several approaches were used to look for structure in the mRNA expression data. We performed an unsupervised hierarchical clustering analysis of 525 tumors and 22 tumor-adjacent normal tissues using the top 3,662 variably expressed genes (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 5</xref>); SigClust analysis identified 12 classes (5 classes with &gt;9 samples/class). We performed a semi-supervised hierarchical cluster analysis using a previously published “intrinsic gene list”<sup><xref rid="R14" ref-type="bibr">14</xref></sup>, which identified 13 classes (9 classes with &gt;9 samples/class) (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 6</xref>). We also classified each sample using the 50-gene PAM50 model<sup><xref rid="R14" ref-type="bibr">14</xref></sup> (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 5</xref>). High concordance was observed between all three, therefore, we used the PAM50-defined subtype predictor as a common classification metric. There were only 8 Normal-like and 8 Claudin-low tumors<sup><xref rid="R26" ref-type="bibr">26</xref></sup>, thus no analyses focused on these two subtypes were performed.</p>
        <p id="P11">MicroRNA expression levels were assayed via Illumina sequencing, using 1222 miRBase<sup><xref rid="R27" ref-type="bibr">27</xref></sup> v16 mature and star strands as the reference database of microRNA transcripts/genes. Seven subtypes were identified by consensus NMF clustering using an abundance matrix containing the 25% most variable microRNAs (306 transcripts/genes or MIMATs). These subtypes correlated with mRNA-subtypes, ER, PR and HER2 clinical status (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 7</xref>). Of note, microRNA groups 4 and 5 showed high overlap with the Basal-like mRNA subtype and contained many <italic toggle="yes">TP53</italic> mutations. The remaining microRNA groups (1–3, 6 and 7) were composed of a mixture of Luminal A, Luminal B and HER2-positive tumors with little correlation with the PAM50 defined subtypes. With the exception of <italic toggle="yes">TP53</italic>, which showed a strong positive correlation, and <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">GATA3</italic> that showed negative associations with groups 4 and 5 respectively, there was little correlation with mutation status and microRNA subtype.</p>
      </sec>
      <sec id="S7">
        <title>DNA methylation</title>
        <p id="P12">llumina Infinium DNA methylation arrays were used to assay 802 breast tumors. Data from HumanMethylation27 (HM27) and HumanMethylation450 (HM450) arrays were combined and filtered to yield a common set of 574 probes used in an unsupervised clustering analysis, which identified five distinct DNA methylation groups (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 8</xref>). Group 3 showed a hyper-methylated phenotype and was significantly enriched for Luminal B mRNA-subtype and under-represented for <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">MAP3K1/MAP2K4</italic> mutations. Group 5 showed the lowest levels of DNA methylation, overlapped with the Basal-like mRNA-subtype, and showed a high frequency of <italic toggle="yes">TP53</italic> mutations. HER2-positive clinical status, or the HER2E mRNA subtype, had only a modest association with the methylation subtypes.</p>
        <p id="P13">A supervised analysis of the DNA methylation and mRNA expression data was performed to compare the DNA methylation Group 3 (N=49) versus all tumors in groups 1, 2, and 4 (excluding Group 5 that consisted predominantly of Basal-like tumors). This analysis identified 4,283 genes differentially methylated (3,735 higher in Group 3 tumors) and 1,899 genes differentially expressed (1,232 downregulated); 490 genes were both methylated and showed lower expression in Group 3 tumors (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table 4</xref>). A DAVID functional annotation analysis identified ‘Extracellular region part’ and ‘Wnt signaling pathway’ to be associated with this 490 gene-set; the Group 3 hyper-methylated samples showed fewer <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">MAP3K1</italic> mutations, and lower expression of Wnt-pathway genes.</p>
      </sec>
      <sec id="S8">
        <title>DNA copy number</title>
        <p id="P14">773 breast tumors were assayed using Affymetrix 6.0 SNP arrays. Segmentation analysis and GISTIC were used to identify focal amplifications/deletions and arm-level gains and losses (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table 5</xref>). These analyses confirmed all previously reported copy number variations and highlighted a number of SMGs including focal amplification of regions containing <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">HER1/EGFR</italic>, <italic toggle="yes">FOXA1</italic>, and <italic toggle="yes">HER2/ERBB2</italic>, as well as focal deletions of regions containing <italic toggle="yes">MLL3</italic>, <italic toggle="yes">PTEN</italic>, <italic toggle="yes">RB1</italic> and <italic toggle="yes">MAP2K4</italic> (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 9</xref>); in all cases, multiple genes were included within each altered region. Importantly, many of these copy number changes correlated with mRNA-subtype including characteristic loss of 5q and gain of 10p in Basal-like cancers<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> and gain of 1q and/or 16q loss in Luminal tumors<sup><xref rid="R4" ref-type="bibr">4</xref></sup>. NMF clustering of GISTIC segments identified five copy number clusters/groups that correlated with mRNA-subtypes, ER, PR and HER2 clinical status, and <italic toggle="yes">TP53</italic> mutation status (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 10</xref>). In addition, this aCGH subtype classification was highly correlated with the aCGH subtypes recently defined by Curtis et al.<sup><xref rid="R29" ref-type="bibr">29</xref></sup>(<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 11</xref>).</p>
      </sec>
      <sec id="S9">
        <title>Reverse Phase Protein Arrays (RPPA)</title>
        <p id="P15">Quantified expression of 171 cancer-related proteins and phospho-proteins by RPPA was performed on 403 breast tumors<sup><xref rid="R30" ref-type="bibr">30</xref></sup>. Unsupervised hierarchical clustering analyses identified seven subtypes; one class contained too few cases for further analysis (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 12</xref>). These protein subtypes were highly concordant with the mRNA-subtypes, particularly with Basal-like and HER2E mRNA subtypes. Closer examination of the HER2-containing RPPA-defined subgroup showed coordinated overexpression of HER2 and HER1 with a strong concordance with phosphorylated HER2 (pY1248) and HER1 (pY992), likely from heterodimerization and cross-phosphorylation. While there is a potential for modest cross reactivity of antibodies against these related total and phosphoproteins, the concordance of phosphorylation of HER2 and HER1 was confirmed using multiple independent antibodies.</p>
        <p id="P16">In RPPA-defined Luminal tumors, there was high protein expression of ER, PR, AR, BCL2, GATA3 and INPP4B, defining mostly Luminal A cancers and a second more heterogeneous protein subgroup composed of both Luminal A and Luminal B cancers. Two potentially novel protein-defined subgroups were identified: Reactive I consisted primarily of a subset of Luminal A tumors, whereas Reactive II consisted of a mixture of mRNA-subtypes. These groups are termed ‘Reactive’ because many of the characteristic proteins are likely produced by the microenvironment and/or cancer-activated fibroblasts including Fibronectin, Caveolin 1 and Collagen VI. These two RPPA groups did not have a marked difference in the % tumor cell content versus each other, or the other protein subtypes, as assessed by SNP array analysis or pathological examination. In addition, supervised analyses of Reactive I vs. II groups using microRNA expression, DNA methylation, mutation, or DNA copy number data identified no significant differences between these groups, while similar supervised analyses using protein and mRNA expression identified many differences.</p>
      </sec>
      <sec id="S10">
        <title>Multi-platform subtype discovery</title>
        <p id="P17">To reveal higher order structure in breast tumors based on multiple data types, significant clusters/subtypes from each of five platforms were analyzed using a multi-platform data matrix subjected to unsupervised Consensus Clustering (<xref rid="F2" ref-type="fig">Figure 2</xref>). This “Cluster of Clusters” (C of C) approach illustrated that Basal-like cancers had the most distinct multi-platform signature since all the different platforms for the Basal-like groups clustered together. To a great extent, the four major C of C subdivisions correlated well with the previously-published mRNA-subtypes (driven in part by the fact that the four intrinsic subtypes were one of the inputs). Therefore, we also performed C of C analysis with no mRNA data present (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 13</xref>) or with the 12 unsupervised mRNA subtypes (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 14</xref>), and in each case 4–6 groups were identified. Recent work by Curtis et al. identified 10 copy number based subgroups in a 997 breast cancer set<sup><xref rid="R29" ref-type="bibr">29</xref></sup>. We evaluated this classification in a C of C analysis instead of our 5-class copy number subtypes, with either the PAM50 (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 15</xref>) or 12 unsupervised mRNA subtypes (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 16</xref>); each of these C of C classifications were highly correlated with PAM50 mRNA-subtypes and with the other C of C analyses (<xref rid="F2" ref-type="fig">Figure 2</xref>). The transcriptional profiling and RPPA platforms demonstrated a high correlation with the consensus structure suggesting that the information content from copy number aberrations, microRNAs, and methylation is captured at the level of gene expression and protein function.</p>
      </sec>
      <sec id="S11">
        <title>Luminal/ER-positive summary analysis</title>
        <p id="P18">Luminal/ER-positive breast cancers are the most heterogeneous in terms of gene expression (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 5</xref>), mutation spectrum (<xref rid="F1" ref-type="fig">Figure 1</xref>), copy number changes (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 9</xref>) and patient outcomes<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup>. One of the most dominant features is high mRNA and protein expression of the luminal expression signature (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 5</xref>), which contains <italic toggle="yes">ESR1</italic>, <italic toggle="yes">GATA3</italic>, <italic toggle="yes">FOXA1</italic>, <italic toggle="yes">XBP1</italic> and <italic toggle="yes">cMYB</italic>; the Luminal/ER-positive cluster also contained the largest number of SMGs. Most notably, <italic toggle="yes">GATA3</italic> and <italic toggle="yes">FOXA1</italic> were mutated in a mutually exclusive fashion, while <italic toggle="yes">ESR1</italic> and <italic toggle="yes">XBP1</italic> were typically highly expressed but infrequently mutated. Mutations in <italic toggle="yes">RUNX1</italic> and its dimerization partner <italic toggle="yes">CBFB</italic> may also play a role in aberrant ER-signaling in Luminals as <italic toggle="yes">RUNX1</italic> functions as an ER “DNA tethering factor”<sup><xref rid="R31" ref-type="bibr">31</xref></sup>. PARADIGM<sup><xref rid="R32" ref-type="bibr">32</xref></sup> analysis comparing Luminal vs. Basal-like cancers further emphasized the presence of a hyperactivated FOXA1/ER complex as a critical network hub differentiating these two tumor subtypes (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 17</xref>).</p>
        <p id="P19">A confirmatory finding here was the high mutation frequency of <italic toggle="yes">PIK3CA</italic> in Luminal/ER-positive breast cancers<sup><xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup>. Through multiple technology platforms, we examined possible relationships between <italic toggle="yes">PIK3CA</italic> mutation, <italic toggle="yes">PTEN</italic> loss, <italic toggle="yes">INPP4B</italic> loss and multiple gene and protein expression signatures of pathway activity. RPPA data demonstrated that pAKT, pS6 and p4EBP1, typical markers of PI3K pathway activation, were not elevated in <italic toggle="yes">PIK3CA</italic>-mutated Luminal A cancers; instead, they were highly expressed in Basal-like and HER2E mRNA-subtypes (the latter having frequent <italic toggle="yes">PIK3CA</italic> mutations) and correlated strongly with <italic toggle="yes">INPP4B</italic> and <italic toggle="yes">PTEN</italic> loss, and to a degree with <italic toggle="yes">PIK3CA</italic> amplification. Similarly, protein<sup><xref rid="R35" ref-type="bibr">35</xref></sup> and three mRNA signatures<sup><xref rid="R36" ref-type="bibr">36</xref>–<xref rid="R38" ref-type="bibr">38</xref></sup> of PI3K pathway activation were enriched in Basal-like over Luminal A cancers (<xref rid="F3" ref-type="fig">Figure 3A</xref>). This apparent disconnect between the presence of <italic toggle="yes">PIK3CA</italic> mutations and biomarkers of pathway activation has been previously noted<sup><xref rid="R35" ref-type="bibr">35</xref></sup>.</p>
        <p id="P20">Another striking Luminal/ER-positive subtype finding was the frequent mutation of <italic toggle="yes">MAP3K1</italic> and <italic toggle="yes">MAP2K4</italic>, which represent two contiguous steps within the p38/JNK1 pathway<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R39" ref-type="bibr">39</xref></sup>. These mutations are predicted to be inactivating, with <italic toggle="yes">MAP2K4</italic> also a target of focal DNA loss in Luminal tumors (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 9</xref>). To explore the possible interplay between <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">MAP3K1/MAP2K4</italic> signaling, MEMo analysis<sup><xref rid="R40" ref-type="bibr">40</xref></sup> was performed to identify mutually exclusive alterations targeting frequently altered genes likely to belong to the same pathway (<xref rid="F4" ref-type="fig">Figure 4</xref>). Across all breast cancers, MEMo identified a set of modules that highlight the differential activation events within the Receptor Tyrosine Kinase (RTK)/PI3K pathway (<xref rid="F4" ref-type="fig">Figure 4A</xref>); mutations of <italic toggle="yes">PIK3CA</italic> were very common in Luminal/ER-positive cancers while <italic toggle="yes">PTEN</italic> loss was more common in Basal-like tumors. Almost all <italic toggle="yes">MAP3K1/MAP2K4</italic> mutations were in Luminal tumors, yet <italic toggle="yes">MAP3K1</italic> and <italic toggle="yes">MAP2K4</italic> appeared almost mutually exclusive relative to one another.</p>
        <p id="P21">The TP53 pathway was differentially inactivated in Luminal/ER-positive breast cancers, with a low <italic toggle="yes">TP53</italic> mutation frequency in Luminal A (12%) and a higher frequency in Luminal B (29%) (<xref rid="F1" ref-type="fig">Figure 1</xref>). In addition to <italic toggle="yes">TP53</italic> itself, a number of other pathway-inactivating events occurred including <italic toggle="yes">ATM</italic> loss and <italic toggle="yes">MDM2</italic> amplification (<xref rid="F3" ref-type="fig">Figure 3B</xref> and <xref rid="F4" ref-type="fig">4B</xref>), both of which occurred more frequently within Luminal B cancers. Gene expression analysis demonstrated that individual markers of functional TP53 (GADD45A and CDKN1A), and TP53 activity<sup><xref rid="R41" ref-type="bibr">41</xref>,<xref rid="R42" ref-type="bibr">42</xref></sup> signatures, were highest in Luminal A (<xref rid="F3" ref-type="fig">Figure 3B</xref>). These data suggest that the TP53 pathway remains largely intact in Luminal A but is often inactivated in the more aggressive Luminal B<sup><xref rid="R43" ref-type="bibr">43</xref></sup>. Other PARADIGM-based pathway differences driving Luminal B versus Luminal A included hyperactivation of transcriptional activity associated with <italic toggle="yes">cMYC</italic> and <italic toggle="yes">FOXM1</italic>/proliferation.</p>
        <p id="P22">The critical retinoblastoma/RB1 pathway also showed mRNA-subtype specific alterations (<xref rid="F3" ref-type="fig">Figure 3C</xref>). RB1 itself, by mRNA and protein expression, was detectable in most Luminal cancers with highest levels within Luminal A. A common oncogenic event was Cyclin D1 amplification and high expression, which preferentially occurred within Luminal tumors, and more specifically within Luminal B. In contrast, the presumed tumor suppressor p18/CDKN2C was at its lowest levels in Luminal A, consistent with observations from mouse models<sup><xref rid="R44" ref-type="bibr">44</xref></sup>. Lastly, RB1 activity signatures were also high in Luminal cancers<sup><xref rid="R45" ref-type="bibr">45</xref>–<xref rid="R47" ref-type="bibr">47</xref></sup>. Luminal A tumors, which have the best prognosis, are the most likely to retain activity of the major tumor suppressors RB1 and TP53.</p>
        <p id="P23">These genomic characterizations also provided clues for druggable targets. We compiled a drug target table in which we defined a target as a gene/protein for which there is an approved or investigational drug in human clinical trials targeting the molecule or canonical pathway (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table 6</xref>). In Luminal/ER-positive cancers, the high frequency of <italic toggle="yes">PIK3CA</italic> mutations suggests that inhibitors of this activated kinase or its signaling pathway may be beneficial. Other potential SMG drug candidates include AKT1 inhibitors (11/12 AKT1 variants were Luminal) and PARP inhibitors for BRCA1/2 mutations. Though still unapproved as biomarkers, many potential copy number-based drug targets were identified including amplifications of FGFRs and IGFR1, as well as Cyclin D1/CDK4/CDK6. A summary of the general findings in Luminal tumors and the other subtypes is presented in <xref rid="T1" ref-type="table">Table 1</xref>.</p>
        <sec id="S12">
          <title>HER2-based classifications and summary analysis</title>
          <p id="P24">DNA amplification of <italic toggle="yes">HER2/ERBB2</italic> was readily evident in this study (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 9</xref>), together with overexpression of multiple HER2-amplicon associated genes that in part, define the HER2-Enriched (HER2E) mRNA-subtype (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 5</xref>). However, not all clinically HER2+ tumors are of the HER2E mRNA-subtype, and not all tumors in the HER2E mRNA-subtype are clinically HER2+. Integrated analysis of the RPPA and mRNA data clearly identified a HER2+ group (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 12</xref>). When the HER2-positive protein and HER2E mRNA-subtypes overlapped, a strong signal of HER1, p-HER1, HER2, and p-HER2 was observed. However, only ~50% of clinically HER2-positive tumors fall into this HER2E-mRNA-subtype/HER2-protein group, the rest of the clinically HER2-positive tumors were observed predominantly in the Luminal mRNA subtypes.</p>
          <p id="P25">These data suggest that there exist at least two types of clinically defined HER2-positive tumors. To identify differences between these groups, a supervised gene expression analysis comparing 36 HER2E-mRNA-subtype/HER2-positive versus 31 Luminal-mRNA-subtype/HER2-positive tumors was performed and identified 302 differentially expressed genes (q-value = 0%) (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 18</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplemental Table 7</xref>). These genes largely track with ER status but also indicated that HER2E-mRNA-subtype/HER2-positive tumors showed significantly higher expression of a number of RTKs including <italic toggle="yes">FGFR4</italic>, <italic toggle="yes">HER1/EGFR</italic>, <italic toggle="yes">HER2</italic> itself, as well as genes within the HER2-amplicon (i.e. <italic toggle="yes">GRB7)</italic>. Conversely, the Luminal-mRNA-subtype/HER2-positive tumors showed higher expression of the Luminal cluster of genes including <italic toggle="yes">GATA3</italic>, <italic toggle="yes">BCL2</italic>, and <italic toggle="yes">ESR1</italic>. Further support for two types of clinically-defined HER2+ disease was evident in the somatic mutation data supervised by either mRNA-subtype or ER status; <italic toggle="yes">TP53</italic> mutations were significantly enriched in HER2E or ER-negative tumors while <italic toggle="yes">GATA3</italic> mutations were only observed in Luminal subtypes or ER-positive tumors.</p>
          <p id="P26">Analysis of the RPPA data according to mRNA-subtype identified 36 differentially expressed proteins (q-value &lt;5%) (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 18G</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplemental Table 8</xref>). The HER1/p-HER1/HER2/p-HER2 signal was again observed and present within the HER2E-mRNA-subtype/HER2-positive tumors, as was high p-SRC and p-S6; conversely, many protein markers of Luminal cancers again distinguished the Luminal-mRNA-subtype/HER2-positive tumors. Given the importance of clinical HER2 status, a more focused analysis was performed based upon the RPPA-defined protein expression of HER2 (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 19</xref>); the results strongly recapitulated findings from the RPPA and mRNA-subtypes including a high correlation between HER2 clinical status, HER2 protein by RPPA, p-HER2, HER1, and p-HER1. These multiple signatures, namely HER2E-mRNA-subtype, HER2-amplicon genes by mRNA expression, and RPPA HER1/p-HER1/HER2/p-HER2 signature, ultimately identify at least two groups/subtypes within clinically HER2+ tumors (<xref rid="T1" ref-type="table">Table 1</xref>). These signatures represent breast cancer biomarker(s) that could potentially predict response to anti-HER2 targeted therapies.</p>
          <p id="P27">Many therapeutic advances have been made for clinically HER2-positive disease. This study has identified additional somatic mutations that represent potential therapeutic targets within this group, including a high frequency of <italic toggle="yes">PIK3CA</italic> mutations (39%), a lower frequency of <italic toggle="yes">PTEN</italic> and <italic toggle="yes">PIK3R1</italic> mutations (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table 6</xref>), and genomic losses of <italic toggle="yes">PTEN</italic> and <italic toggle="yes">INPP4B</italic>. Other possible druggable mutations included variants within HER-family members including two somatic mutations in <italic toggle="yes">HER2</italic>, two within <italic toggle="yes">HER1/EGFR</italic>, and five within <italic toggle="yes">HER3</italic>. Pertuzumab, in combination with trastuzumab, targets the HER2-HER3 heterodimer<sup><xref rid="R48" ref-type="bibr">48</xref></sup>, however, these data suggest that targeting HER1 with HER2 could also be beneficial. Lastly, the HER2E-mRNA-subtype typically showed high aneuploidy, the highest somatic mutation rate (<xref rid="T1" ref-type="table">Table 1</xref>), and DNA amplification of other potential therapeutic targets including <italic toggle="yes">FGFRs</italic>, <italic toggle="yes">HER1/EGFR</italic>, <italic toggle="yes">CDK4</italic> and <italic toggle="yes">Cyclin D1</italic>.</p>
        </sec>
      </sec>
      <sec id="S13">
        <title>Basal-like summary analysis</title>
        <p id="P28">The Basal-like subtype was discovered more than a decade ago by first-generation cDNA microarrays<sup><xref rid="R13" ref-type="bibr">13</xref></sup>. These tumors are often referred to as Triple-Negative Breast Cancers (TNBC) because most Basal-like tumors are typically negative for ER, PR and HER2. However, ~75% of TNBC are Basal-like with the other 25% comprised of all other mRNA-subtypes<sup><xref rid="R6" ref-type="bibr">6</xref></sup>. In this data set, there was a high degree of overlap between these two distinctions with 76 TNBC, 81 Basal-like, and 65 that were both TNBC and Basal-like. Given the known heterogeneity of TNBC, and that the Basal-like subtype proved to be distinct on every platform, we choose to use the Basal-like distinction for comparative analyses.</p>
        <p id="P29">Basal-like tumors showed a high frequency of <italic toggle="yes">TP53</italic> mutations (80%)<sup><xref rid="R9" ref-type="bibr">9</xref></sup>, which when combined with inferred TP53 pathway activity suggests that loss of TP53 function occurs within most, if not all, Basal-like cancers (<xref rid="F3" ref-type="fig">Figure 3B</xref>). In addition to loss of <italic toggle="yes">TP53</italic>, a MEMo analysis reconfirmed that loss of <italic toggle="yes">RB1</italic> and <italic toggle="yes">BRCA1</italic> are Basal-like features (<xref rid="F4" ref-type="fig">Figure 4C</xref>)<sup><xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R49" ref-type="bibr">49</xref></sup>. <italic toggle="yes">PIK3CA</italic> was the next most commonly mutated gene (~9%); however, inferred PI3K pathway activity, whether from gene<sup><xref rid="R36" ref-type="bibr">36</xref>–<xref rid="R38" ref-type="bibr">38</xref></sup>, protein<sup><xref rid="R35" ref-type="bibr">35</xref></sup>, or high PI3K/AKT pathway activities, was highest in Basal-like cancers (<xref rid="F3" ref-type="fig">Figure 3A</xref>). Alternative means of activating the PI3K-pathway in Basal-like cancers likely includes loss of <italic toggle="yes">PTEN</italic> and <italic toggle="yes">INPP4B</italic> and/or amplification of <italic toggle="yes">PIK3CA</italic>. A recent paper from Shah et al.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> performed exome sequencing of 102 TNBC. Five of the top six most frequent TNBCs mutations in Shah et al. were also observed at a similar frequency in our TNBC subset (Myo3A not present here); of those five, three passed our test as a significantly mutated gene in TNBCs (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table 2</xref>).</p>
        <p id="P30">Expression features of Basal-like tumors include a characteristic signature containing Keratins 5, 6 and 17 and high expression of genes associated with cell proliferation (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 5</xref>). A PARADIGM<sup><xref rid="R32" ref-type="bibr">32</xref></sup> analysis of Basal-like versus Luminal tumors emphasized the importance of hyperactivated FOXM1 as a transcriptional driver of this enhanced proliferation signature (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 17</xref>). PARADIGM also identified hyperactivated cMYC and HIF1α/ARNT network hubs as key regulatory features of Basal-like cancers. Even though chromosome 8q24 is amplified across all subtypes (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 9</xref>), high cMYC activation appears to be a Basal-like characteristic<sup><xref rid="R50" ref-type="bibr">50</xref></sup>.</p>
        <p id="P31">Given the striking contrasts between Basal-like and Luminal/HER2E subtypes, we performed a MEMo analysis on Basal-like tumors alone. The top-scoring module included <italic toggle="yes">ATM</italic> mutations, <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> inactivation, <italic toggle="yes">RB1</italic> loss and <italic toggle="yes">Cyclin E1</italic> amplification (<xref rid="F4" ref-type="fig">Figure 4C</xref>). Interestingly, these same modules were identified previously for Serous Ovarian cancers<sup><xref rid="R40" ref-type="bibr">40</xref></sup>. Furthermore, the Basal-like (and TNBC) mutation spectrum was reminiscent of the spectrum seen in Serous Ovarian cancers<sup><xref rid="R51" ref-type="bibr">51</xref></sup> with only one gene (i.e. <italic toggle="yes">TP53</italic>) at &gt;10% mutation frequency. To explore possible similarities between Serous Ovarian and the breast Basal-like cancers, we performed a number of analyses comparing Ovarian vs. breast Luminal, Ovarian vs. breast Basal-like, and breast Basal-like vs. breast Luminal (<xref rid="F5" ref-type="fig">Figure 5</xref>). Comparing copy number landscapes, we observed several common features between Ovarian and Basal-like tumors including widespread genomic instability and common gains of 1q, 3q, 8q and 12p, and loss of 4q, 5q and 8p (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 20A</xref>). Using a more global copy number comparison, we examined the overall fraction of the genome altered and the overall copy number correlation of Ovarian cancers versus each breast cancer mRNA-subtype (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 20A, B</xref>); in both cases, Basal-like tumors were the most similar to the Serous Ovarian carcinomas.</p>
        <p id="P32">We systematically looked for other common features between Serous Ovarian and Basal-like when each was compared to Luminal. We identified: 1) <italic toggle="yes">BRCA1</italic> inactivation, 2) <italic toggle="yes">RB1</italic> loss and <italic toggle="yes">Cyclin E1</italic> amplification, 3) high expression of <italic toggle="yes">AKT3</italic>, 4) <italic toggle="yes">cMYC</italic> amplification and high expression, and 5) a high frequency of <italic toggle="yes">TP53</italic> mutations (<xref rid="F5" ref-type="fig">Figure 5A</xref>). An additional supervised analysis of a large, external multi-tumor type transcriptomic dataset (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE2109">GSE2109</ext-link>) was performed where each TCGA breast tumor expression profile was compared via a correlation analysis to that of each tumor in the multi-tumor set. Basal-like breast cancers clearly showed high mRNA expression correlations with Serous Ovarian cancers, as well as with Lung Squamous carcinomas (<xref rid="F5" ref-type="fig">Figure 5B</xref>). A PARADIGM analysis that calculates whether a gene or pathway feature is both differentially activated in Basal-like versus Luminal cancers and has higher overall activity across the TCGA Ovarian samples was performed; this identified comparably high pathway activity of the HIF1α/ARNT, cMYC, and FOXM1 regulatory hubs in both Ovarian and Basal-like cancers (<xref rid="SD1" ref-type="supplementary-material">Supplemental Figure 20C</xref>). The common findings of <italic toggle="yes">TP53</italic>, <italic toggle="yes">RB1</italic> and <italic toggle="yes">BRCA1</italic> loss, with <italic toggle="yes">cMYC</italic> amplification strongly suggest that these are shared driving events for Basal-like and Serous Ovarian carcinogenesis. This suggests that common therapeutic approaches should be considered, which is supported by the activity of platinum analogs, and taxanes, in breast Basal-like and Serous Ovarian cancers.</p>
        <p id="P33">Given that most Basal-like cancers are TNBC, finding new drug targets for this group is critical. Unfortunately, the somatic mutation repertoire for Basal-like breast cancers has not provided a common target aside from <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2.</italic> Here we note that ~20% of Basal-like tumors had a germline (n=12) and/or somatic (n=8) <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> variant, which suggests 1 in 5 Basal-like patients might benefit from PARP inhibitors and/or platinum compounds<sup><xref rid="R52" ref-type="bibr">52</xref>,<xref rid="R53" ref-type="bibr">53</xref></sup>. The copy number landscape of Basal-like cancers showed multiple amplifications and deletions, some of which may provide therapeutic targets (<xref rid="SD5" ref-type="supplementary-material">Supplemental Table 6</xref>). Potential targets include losses of <italic toggle="yes">PTEN</italic> and <italic toggle="yes">INPP4B</italic>, both of which have been shown to sensitize cell lines to PI3K pathway inhibitors<sup><xref rid="R54" ref-type="bibr">54</xref>,<xref rid="R55" ref-type="bibr">55</xref></sup>. Interestingly, many of the components of the PI3K and RAS-RAF-MEK pathway were amplified (but not typically mutated) in Basal-like cancers including <italic toggle="yes">PIK3CA</italic> (49%), <italic toggle="yes">KRAS</italic> (32%), <italic toggle="yes">BRAF</italic> (30%), and <italic toggle="yes">HER1/EGFR</italic> (23%). Other RTKs that are plausible drug targets and amplified in some Basal-like cancers include <italic toggle="yes">FGFR1</italic>, <italic toggle="yes">FGFR2</italic>, <italic toggle="yes">IGFR1</italic>, c-<italic toggle="yes">KIT, MET</italic> and <italic toggle="yes">PDGFRA</italic>. Lastly, the PARADIGM identification of high HIF1α/ARNT pathway activity suggest that these malignancies might be susceptible to angiogenesis inhibitors and/or bioreductive drugs that become activated under hypoxic conditions.</p>
      </sec>
      <sec id="S14">
        <title>Summary</title>
        <p id="P34">The integrated molecular analyses of breast carcinomas we report significantly extends our knowledge base to produce a comprehensive catalog of likely genomic drivers of the most common breast cancer subtypes (<xref rid="T1" ref-type="table">Table 1</xref>). Our novel observation that diverse genetic and epigenetic alterations converge phenotypically into four main breast cancer classes is not only consistent with convergent evolution of gene circuits as seen across multiple organisms, but also with models of breast cancer clonal expansion and <italic toggle="yes">in vivo</italic> cell selection proposed to explain the phenotypic heterogeneity observed within defined breast cancer subtypes.</p>
      </sec>
      <sec id="S15">
        <title>Methods summary</title>
        <p id="P35">Specimens were obtained from patients with appropriate consent from institutional review boards. Using a co-isolation protocol, DNA and RNA were purified. In total, 800 patients were assayed on at least one platform. Different numbers of patients were used for each platform using the largest number of patients available at time of data freeze; 466 samples (463 patients) were in common across 5/6 platforms (excluding RPPA) and 348 patients were in common on 6/6 platforms. Technology platforms used include: 1) gene expression DNA microarrays<sup><xref rid="R51" ref-type="bibr">51</xref></sup>, 2) DNA methylation arrays, 3) microRNA sequencing, 4) Affymetrix SNP arrays, 5) exome sequencing, and 6) Reverse Phase Protein Arrays. Each platform, except for the exome sequencing, was used in a <italic toggle="yes">de novo</italic> subtype discovery analysis (<xref rid="SD1" ref-type="supplementary-material">Supplemental Methods</xref>) which were included in a single analysis to define an overall subtype architecture. Additional integrated across platform computational analyses were preformed including PARADIGM<sup><xref rid="R32" ref-type="bibr">32</xref></sup> and MEMo<sup><xref rid="R40" ref-type="bibr">40</xref></sup>.</p>
        <p id="P36">All of the primary sequence files are deposited in CGHub (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cghub.ucsc.edu/">https://cghub.ucsc.edu/</ext-link>); all other data including mutation annotation file are deposited at the Data Coordinating Center (DCC) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>). Sample lists, data matrices and <xref rid="SD1" ref-type="supplementary-material">supporting data</xref> can be found at (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://tcga-data.nci.nih.gov/docs/publications/brca_2012/">http://tcga-data.nci.nih.gov/docs/publications/brca_2012/</ext-link>). The data can be explored via the ISB Regulome Explorer (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://explorer.cancerregulome.org/">http://explorer.cancerregulome.org/</ext-link>) and the cBio Cancer Genomics Portal (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cbioportal.org">http://cbioportal.org</ext-link>). Data descriptions can be found at (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wiki.nci.nih.gov/display/TCGA/TCGA+Data+Primer">https://wiki.nci.nih.gov/display/TCGA/TCGA+Data+Primer</ext-link>) and in <xref rid="SD1" ref-type="supplementary-material">Supplementary Methods</xref>. Reprints and permissions information is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="www.nature.com/reprints">www.nature.com/reprints</ext-link>.</p>
      </sec>
      <sec sec-type="supplementary-material" id="S16">
        <title>Supplementary Material</title>
        <supplementary-material content-type="local-data" id="SD1" position="float" orientation="portrait">
          <label>1</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS393293-supplement-1.pdf" mimetype="application" mime-subtype="pdf" orientation="portrait" id="d37e1342" position="anchor"/>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="SD2" position="float" orientation="portrait">
          <label>2</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS393293-supplement-2.xls" mimetype="application" mime-subtype="vnd.ms-excel" orientation="portrait" id="d37e1346" position="anchor"/>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="SD3" position="float" orientation="portrait">
          <label>3</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS393293-supplement-3.xls" mimetype="application" mime-subtype="vnd.ms-excel" orientation="portrait" id="d37e1350" position="anchor"/>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="SD4" position="float" orientation="portrait">
          <label>4</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS393293-supplement-4.xls" mimetype="application" mime-subtype="vnd.ms-excel" orientation="portrait" id="d37e1354" position="anchor"/>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="SD5" position="float" orientation="portrait">
          <label>5</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS393293-supplement-5.xls" mimetype="application" mime-subtype="vnd.ms-excel" orientation="portrait" id="d37e1358" position="anchor"/>
        </supplementary-material>
      </sec>
    </body>
    <back>
      <ack id="S17">
        <p>We thank Margi Sheth and Susan Lucas for administrative coordination of TCGA activities, and Chris Gunter for critical reading of the manuscript. This work was supported by the following grants from the USA National Institutes of Health: U24CA143883, U24CA143858, U24CA143840, U24CA143799, U24CA143835, U24CA143845, U24CA143882, U24CA143867, U24CA143866, U24CA143848, U24CA144025, U54HG003079, P50CA116201 and P50CA58223. Additional support was provided by the Susan G. Komen for the Cure, the US Department of Defense through the Henry M. Jackson Foundation for the Advancement of Military Medicine, and the Breast Cancer Research Foundation. The views expressed in this paper are those of the authors and do not reflect the official policy of the Department of Defense, or U.S. Government.</p>
      </ack>
      <fn-group>
        <fn id="FN2">
          <label>1</label>
          <p>The Genome Institute, Washington University, St Louis, Missouri 63108, USA</p>
        </fn>
        <fn id="FN3">
          <label>2</label>
          <p>Department of Genetics, Washington University, St Louis, Missouri 63110, USA</p>
        </fn>
        <fn id="FN4">
          <label>3</label>
          <p>Siteman Cancer Center, Washington University, St Louis, Missouri 63110, USA</p>
        </fn>
        <fn id="FN5">
          <label>4</label>
          <p>Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z, Canada</p>
        </fn>
        <fn id="FN6">
          <label>5</label>
          <p>The Broad Institute of MIT and Harvard, Cambridge, MA 02142</p>
        </fn>
        <fn id="FN7">
          <label>6</label>
          <p>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02115</p>
        </fn>
        <fn id="FN8">
          <label>7</label>
          <p>Department of Medicine, Harvard Medical School, Boston, MA 02215</p>
        </fn>
        <fn id="FN9">
          <label>8</label>
          <p>Departments of Cancer Biology and Medical Oncology, and the Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, 02115</p>
        </fn>
        <fn id="FN10">
          <label>9</label>
          <p>Department of Medical Oncology and the Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, 02115</p>
        </fn>
        <fn id="FN11">
          <label>10</label>
          <p>Department of Pathology, Harvard Medical School, Boston, MA02215</p>
        </fn>
        <fn id="FN12">
          <label>11</label>
          <p>Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02115 USA</p>
        </fn>
        <fn id="FN13">
          <label>12</label>
          <p>The Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115 USA</p>
        </fn>
        <fn id="FN14">
          <label>13</label>
          <p>Department of Genetics, Harvard Medical School and Division of Genetics, Brigham and Women’s Hospital, Boston, MA 02115 USA</p>
        </fn>
        <fn id="FN15">
          <label>14</label>
          <p>Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN16">
          <label>15</label>
          <p>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN17">
          <label>16</label>
          <p>Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN18">
          <label>17</label>
          <p>Institute for Pharmacogenetics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN19">
          <label>18</label>
          <p>Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN20">
          <label>19</label>
          <p>Department of Internal Medicine, Division of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA</p>
        </fn>
        <fn id="FN21">
          <label>20</label>
          <p>USC Epigenome Center, University of Southern California, Los Angeles, CA 90033 USA</p>
        </fn>
        <fn id="FN22">
          <label>21</label>
          <p>Cancer Biology Division, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231 USA</p>
        </fn>
        <fn id="FN23">
          <label>22</label>
          <p>Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030</p>
        </fn>
        <fn id="FN24">
          <label>23</label>
          <p>Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030</p>
        </fn>
        <fn id="FN25">
          <label>24</label>
          <p>Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030</p>
        </fn>
        <fn id="FN26">
          <label>25</label>
          <p>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030</p>
        </fn>
        <fn id="FN27">
          <label>26</label>
          <p>The Eli and Edythe L. Broad Institute of Massachusetts Institute Of Technology and Harvard University, Cambridge, MA 02142 USA</p>
        </fn>
        <fn id="FN28">
          <label>27</label>
          <p>Institute for Applied Cancer Science, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054</p>
        </fn>
        <fn id="FN29">
          <label>28</label>
          <p>Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054</p>
        </fn>
        <fn id="FN30">
          <label>29</label>
          <p>Division of Genetics, Brigham and Women’s Hospital, Boston, MA 02115 USA</p>
        </fn>
        <fn id="FN31">
          <label>30</label>
          <p>Informatics Program, Children’s Hospital, Boston, MA 02115 USA</p>
        </fn>
        <fn id="FN32">
          <label>31</label>
          <p>Institute for Systems Biology, Seattle, WA 98109 USA</p>
        </fn>
        <fn id="FN33">
          <label>32</label>
          <p>Tampere University of Technology, Tampere, Finland</p>
        </fn>
        <fn id="FN34">
          <label>33</label>
          <p>Cancer Genomics Core Laboratory, M.D. Anderson Cancer Center, Houston, TX 77030 USA</p>
        </fn>
        <fn id="FN35">
          <label>34</label>
          <p>Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 USA</p>
        </fn>
        <fn id="FN36">
          <label>35</label>
          <p>Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 USA</p>
        </fn>
        <fn id="FN37">
          <label>36</label>
          <p>Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 USA</p>
        </fn>
        <fn id="FN38">
          <label>37</label>
          <p>Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland OR 97239</p>
        </fn>
        <fn id="FN39">
          <label>38</label>
          <p>Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA</p>
        </fn>
        <fn id="FN40">
          <label>39</label>
          <p>Kleberg Center for Molecular Markers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 US</p>
        </fn>
        <fn id="FN41">
          <label>40</label>
          <p>Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA</p>
        </fn>
        <fn id="FN42">
          <label>41</label>
          <p>Department of Biomolecular Engineering and Center for Biomolecular Science and Engineering, University of California Santa Cruz, Santa Cruz, CA 95064 USA</p>
        </fn>
        <fn id="FN43">
          <label>42</label>
          <p>Howard Hughes Medical Institute, University of California Santa Cruz, Santa Cruz, CA 95064 USA</p>
        </fn>
        <fn id="FN44">
          <label>43</label>
          <p>Buck Institute for Research on Aging, Novato, CA 94945 USA</p>
        </fn>
        <fn id="FN45">
          <label>44</label>
          <p>Center for Bioinformatics and Information Technology, National Cancer Institute, Rockville, MD</p>
        </fn>
        <fn id="FN46">
          <label>45</label>
          <p>The Ohio State University College of Medicine, Department of Pathology, Columbus, OH 43205</p>
        </fn>
        <fn id="FN47">
          <label>46</label>
          <p>The Ohio State University College of Medicine, Department Pediatrics, Columbus, OH 43205</p>
        </fn>
        <fn id="FN48">
          <label>47</label>
          <p>The Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205</p>
        </fn>
        <fn id="FN49">
          <label>48</label>
          <p>ABS Inc. Indianapolis, IN 46204 USA</p>
        </fn>
        <fn id="FN50">
          <label>49</label>
          <p>ABS Inc. Wilmington DE 19801 USA</p>
        </fn>
        <fn id="FN51">
          <label>50</label>
          <p>Indiana University School of Medicine, Indianapolis, Indiana 46202 USA</p>
        </fn>
        <fn id="FN52">
          <label>51</label>
          <p>Helen F. Graham Cancer Center, Christiana Care, Newark, Delaware 19713 USA</p>
        </fn>
        <fn id="FN53">
          <label>52</label>
          <p>Moscow City Clinical Oncology Dispensary #1 and the Central IHC Laboratory of the Moscow Health Department, Moscow, Russia</p>
        </fn>
        <fn id="FN54">
          <label>53</label>
          <p>Russian Cancer Research Center, Moscow, Russia</p>
        </fn>
        <fn id="FN55">
          <label>54</label>
          <p>Cureline, Inc., South San Francisco, CA, USA</p>
        </fn>
        <fn id="FN56">
          <label>55</label>
          <p>Department of Surgery, Duke University Medical Center, Durham, NC 27710 USA</p>
        </fn>
        <fn id="FN57">
          <label>56</label>
          <p>The Greater Poland Cancer Centre, Pozna, 61-866, Poland</p>
        </fn>
        <fn id="FN58">
          <label>57</label>
          <p>Poznan University of Medical Sciences, Pozna, 61-701, Poland</p>
        </fn>
        <fn id="FN59">
          <label>58</label>
          <p>ILSBio, LLC, Chestertown, MD 21620, USA</p>
        </fn>
        <fn id="FN60">
          <label>59</label>
          <p>Ministry of Health, Hanoi, Vietnam</p>
        </fn>
        <fn id="FN61">
          <label>60</label>
          <p>ILSBio LLC, Karachi, Pakistan</p>
        </fn>
        <fn id="FN62">
          <label>61</label>
          <p>Hue Central Hospital, Hue City, Vietnam</p>
        </fn>
        <fn id="FN63">
          <label>62</label>
          <p>Stanford University Medical Center, Stanford, CA 94305, USA</p>
        </fn>
        <fn id="FN64">
          <label>63</label>
          <p>Center for Minority Health Research, University of Texas, M.D. Anderson Cancer Center, Houston, TX 07703</p>
        </fn>
        <fn id="FN65">
          <label>64</label>
          <p>National Cancer Institute, Hanoi, Vietnam</p>
        </fn>
        <fn id="FN66">
          <label>65</label>
          <p>Ho Chi Minh City Cancer Center, Vietnam</p>
        </fn>
        <fn id="FN67">
          <label>66</label>
          <p>Can Tho Cancer Center, Can Tho, Vietnam</p>
        </fn>
        <fn id="FN68">
          <label>67</label>
          <p>International Genomics Consortium, Phoenix, AZ 85004 USA</p>
        </fn>
        <fn id="FN69">
          <label>68</label>
          <p>Mayo Clinic, Rochester, MN 55905</p>
        </fn>
        <fn id="FN70">
          <label>69</label>
          <p>Department of Surgery, Breast Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065</p>
        </fn>
        <fn id="FN71">
          <label>70</label>
          <p>Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA</p>
        </fn>
        <fn id="FN72">
          <label>71</label>
          <p>University of California at San Francisco; San Francisco, CA 94143</p>
        </fn>
        <fn id="FN73">
          <label>72</label>
          <p>Cancer Diagnostics; Nichols Institute, Quest Diagnostics; San Juan Capistrano, CA 92675</p>
        </fn>
        <fn id="FN74">
          <label>73</label>
          <p>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115</p>
        </fn>
        <fn id="FN75">
          <label>74</label>
          <p>UNC Tissue Procurement Facility, Department of Pathology, UNC Lineberger Cancer Center, Chapel Hill, NC 27599, USA</p>
        </fn>
        <fn id="FN76">
          <label>75</label>
          <p>Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY 14263 USA</p>
        </fn>
        <fn id="FN77">
          <label>76</label>
          <p>Department of Pathology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA.</p>
        </fn>
        <fn id="FN78">
          <label>77</label>
          <p>University of Pittsburgh, Pittsburgh, PA, 15213 USA</p>
        </fn>
        <fn id="FN79">
          <label>78</label>
          <p>Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh PA 15213 USA</p>
        </fn>
        <fn id="FN80">
          <label>79</label>
          <p>Walter Reed National Military Medical Center, Bethesda, MD 20899-5600</p>
        </fn>
        <fn id="FN81">
          <label>80</label>
          <p>Windber Research Institute, Windber, PA 15963</p>
        </fn>
        <fn id="FN82">
          <label>81</label>
          <p>MDR Global, LLC, Windber, PA 15963</p>
        </fn>
        <fn id="FN83">
          <label>82</label>
          <p>Breast Cancer Program, Washington University, St. Louis, MO, USA</p>
        </fn>
        <fn id="FN84">
          <label>83</label>
          <p>Department of Internal Medicine, Division of Oncology, Washington University, St. Louis, MO, USA</p>
        </fn>
        <fn id="FN85">
          <label>84</label>
          <p>Institute for Genomics and Systems Biology, University of Chicago, Chicago IL</p>
        </fn>
        <fn id="FN86">
          <label>85</label>
          <p>Center for Clinical Cancer Genetics, The University of Chicago, Chicago, IL 60637, USA</p>
        </fn>
        <fn id="FN87">
          <label>86</label>
          <p>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110</p>
        </fn>
        <fn id="FN88">
          <label>87</label>
          <p>SRA International, 4300 Fair Lakes Court, Fairfax, VA 22033</p>
        </fn>
        <fn id="FN89">
          <label>88</label>
          <p>The Cancer Genome Atlas Program Office, Center for Cancer Genomics, National Cancer Institute, Bethesda, MD</p>
        </fn>
        <fn id="FN90">
          <label>89</label>
          <p>TCGA Consultant, Scimentis, LLC, Atlanta, GA</p>
        </fn>
        <fn id="FN91">
          <label>90</label>
          <p>MLF Consulting, Arlington, MA 02474 USA</p>
        </fn>
        <fn id="FN92">
          <label>91</label>
          <p>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892</p>
        </fn>
      </fn-group>
      <ref-list>
        <ref id="R1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Paik</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer</article-title>
            <source>N Engl J Med</source>
            <volume>351</volume>
            <fpage>2817</fpage>
            <lpage>2826</lpage>
            <year>2004</year>
            <pub-id pub-id-type="pmid">15591335</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa041588</pub-id>
          </element-citation>
        </ref>
        <ref id="R2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>van ‘t Veer</surname>
                <given-names>LJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Gene expression profiling predicts clinical outcome of breast cancer</article-title>
            <source>Nature</source>
            <volume>415</volume>
            <fpage>530</fpage>
            <lpage>536</lpage>
            <year>2002</year>
            <pub-id pub-id-type="pmid">11823860</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/415530a</pub-id>
          </element-citation>
        </ref>
        <ref id="R3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Slamon</surname>
                <given-names>DJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene</article-title>
            <source>Science</source>
            <volume>235</volume>
            <fpage>177</fpage>
            <lpage>182</lpage>
            <year>1987</year>
            <pub-id pub-id-type="pmid">3798106</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.3798106</pub-id>
          </element-citation>
        </ref>
        <ref id="R4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Chin</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genomic and transcriptional aberrations linked to breast cancer pathophysiologies</article-title>
            <source>Cancer Cell</source>
            <volume>10</volume>
            <fpage>529</fpage>
            <lpage>541</lpage>
            <comment>S1535-6108(06)00315-1 [pii]</comment>
            <pub-id pub-id-type="doi">10.1016/j.ccr.2006.10.009</pub-id>
            <year>2006</year>
            <pub-id pub-id-type="pmid">17157792</pub-id>
          </element-citation>
        </ref>
        <ref id="R5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bergamaschi</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer</article-title>
            <source>Genes Chromosomes Cancer</source>
            <volume>45</volume>
            <fpage>1033</fpage>
            <lpage>1040</lpage>
            <year>2006</year>
            <pub-id pub-id-type="pmid">16897746</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gcc.20366</pub-id>
          </element-citation>
        </ref>
        <ref id="R6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Perou</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Molecular stratification of triple-negative breast cancers</article-title>
            <source>Oncologist</source>
            <volume>16</volume>
            <issue>Suppl 1</issue>
            <fpage>61</fpage>
            <lpage>70</lpage>
            <pub-id pub-id-type="doi">10.1634/theoncologist.2011-S1-61</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21278442</pub-id>
          </element-citation>
        </ref>
        <ref id="R7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Sorlie</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Repeated observation of breast tumor subtypes in independent gene expression data sets</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <volume>100</volume>
            <fpage>8418</fpage>
            <lpage>8423</lpage>
            <year>2003</year>
            <pub-id pub-id-type="pmid">12829800</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0932692100</pub-id>
            <pub-id pub-id-type="pmcid">PMC166244</pub-id>
          </element-citation>
        </ref>
        <ref id="R8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Foulkes</surname>
                <given-names>WD</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer</article-title>
            <source>J Natl Cancer Inst</source>
            <volume>95</volume>
            <fpage>1482</fpage>
            <lpage>1485</lpage>
            <year>2003</year>
            <pub-id pub-id-type="pmid">14519755</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djg050</pub-id>
          </element-citation>
        </ref>
        <ref id="R9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Carey</surname>
                <given-names>LA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study</article-title>
            <source>Jama</source>
            <volume>295</volume>
            <fpage>2492</fpage>
            <lpage>2502</lpage>
            <year>2006</year>
            <pub-id pub-id-type="pmid">16757721</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.295.21.2492</pub-id>
          </element-citation>
        </ref>
        <ref id="R10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ding</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genome remodelling in a basal-like breast cancer metastasis and xenograft</article-title>
            <source>Nature</source>
            <volume>464</volume>
            <fpage>999</fpage>
            <lpage>1005</lpage>
            <comment>nature08989 [pii]</comment>
            <pub-id pub-id-type="doi">10.1038/nature08989</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20393555</pub-id>
            <pub-id pub-id-type="pmcid">PMC2872544</pub-id>
          </element-citation>
        </ref>
        <ref id="R11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shah</surname>
                <given-names>SP</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution</article-title>
            <source>Nature</source>
            <volume>461</volume>
            <fpage>809</fpage>
            <lpage>813</lpage>
            <pub-id pub-id-type="doi">10.1038/nature08489</pub-id>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19812674</pub-id>
          </element-citation>
        </ref>
        <ref id="R12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shah</surname>
                <given-names>SP</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The clonal and mutational evolution spectrum of primary triple-negative breast cancers</article-title>
            <source>Nature</source>
            <pub-id pub-id-type="doi">10.1038/nature10933</pub-id>
            <year>2012</year>
            <pub-id pub-id-type="pmcid">PMC3863681</pub-id>
            <pub-id pub-id-type="pmid">22495314</pub-id>
          </element-citation>
        </ref>
        <ref id="R13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Perou</surname>
                <given-names>CM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Molecular portraits of human breast tumours</article-title>
            <source>Nature</source>
            <volume>406</volume>
            <fpage>747</fpage>
            <lpage>752</lpage>
            <year>2000</year>
            <pub-id pub-id-type="pmid">10963602</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35021093</pub-id>
          </element-citation>
        </ref>
        <ref id="R14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Parker</surname>
                <given-names>JS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes</article-title>
            <source>J Clin Oncol</source>
            <comment>JCO.2008.18.1370 [pii]</comment>
            <pub-id pub-id-type="doi">10.1200/JCO.2008.18.1370</pub-id>
            <year>2009</year>
            <pub-id pub-id-type="pmcid">PMC2667820</pub-id>
            <pub-id pub-id-type="pmid">19204204</pub-id>
          </element-citation>
        </ref>
        <ref id="R15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gonzalez-Perez</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Lopez-Bigas</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel</article-title>
            <source>Am J Hum Genet</source>
            <volume>88</volume>
            <fpage>440</fpage>
            <lpage>449</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ajhg.2011.03.004</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21457909</pub-id>
            <pub-id pub-id-type="pmcid">PMC3071923</pub-id>
          </element-citation>
        </ref>
        <ref id="R16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bamshad</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome</article-title>
            <source>Nat Genet</source>
            <volume>16</volume>
            <fpage>311</fpage>
            <lpage>315</lpage>
            <pub-id pub-id-type="doi">10.1038/ng0797-311</pub-id>
            <year>1997</year>
            <pub-id pub-id-type="pmid">9207801</pub-id>
          </element-citation>
        </ref>
        <ref id="R17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Li</surname>
                <given-names>QY</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family</article-title>
            <source>Nat Genet</source>
            <volume>15</volume>
            <fpage>21</fpage>
            <lpage>29</lpage>
            <pub-id pub-id-type="doi">10.1038/ng0197-21</pub-id>
            <year>1997</year>
            <pub-id pub-id-type="pmid">8988164</pub-id>
          </element-citation>
        </ref>
        <ref id="R18">
          <label>18</label>
          <element-citation publication-type="journal">
            <collab>The Cancer Genome Atlas Research Network et al</collab>
            <article-title>Comprehensive genomic characterization defines human glioblastoma genes and core pathways</article-title>
            <source>Nature</source>
            <year>2008</year>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11903</pub-id>
            <pub-id pub-id-type="pmid">23389443</pub-id>
          </element-citation>
        </ref>
        <ref id="R19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cheung</surname>
                <given-names>LW</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability</article-title>
            <source>Cancer discovery</source>
            <volume>1</volume>
            <fpage>170</fpage>
            <lpage>185</lpage>
            <pub-id pub-id-type="doi">10.1158/2159-8290.CD-11-0039</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21984976</pub-id>
            <pub-id pub-id-type="pmcid">PMC3187555</pub-id>
          </element-citation>
        </ref>
        <ref id="R20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Malcovati</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms</article-title>
            <source>Blood</source>
            <volume>118</volume>
            <fpage>6239</fpage>
            <lpage>6246</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2011-09-377275</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21998214</pub-id>
            <pub-id pub-id-type="pmcid">PMC3236114</pub-id>
          </element-citation>
        </ref>
        <ref id="R21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>SF3B1and other novel cancer genes in chronic lymphocytic leukemia</article-title>
            <source>N Engl J Med</source>
            <volume>365</volume>
            <fpage>2497</fpage>
            <lpage>2506</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa1109016</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">22150006</pub-id>
            <pub-id pub-id-type="pmcid">PMC3685413</pub-id>
          </element-citation>
        </ref>
        <ref id="R22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ding</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Somatic mutations affect key pathways in lung adenocarcinoma</article-title>
            <source>Nature</source>
            <volume>455</volume>
            <fpage>1069</fpage>
            <lpage>1075</lpage>
            <pub-id pub-id-type="doi">10.1038/nature07423</pub-id>
            <year>2008</year>
            <pub-id pub-id-type="pmid">18948947</pub-id>
            <pub-id pub-id-type="pmcid">PMC2694412</pub-id>
          </element-citation>
        </ref>
        <ref id="R23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Johnson</surname>
                <given-names>GL</given-names>
              </name>
              <name name-style="western">
                <surname>Lapadat</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases</article-title>
            <source>Science</source>
            <volume>298</volume>
            <fpage>1911</fpage>
            <lpage>1912</lpage>
            <pub-id pub-id-type="doi">10.1126/science.1072682</pub-id>
            <year>2002</year>
            <pub-id pub-id-type="pmid">12471242</pub-id>
          </element-citation>
        </ref>
        <ref id="R24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Usary</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutation of GATA3 in human breast tumors</article-title>
            <source>Oncogene</source>
            <volume>23</volume>
            <fpage>7669</fpage>
            <lpage>7678</lpage>
            <year>2004</year>
            <pub-id pub-id-type="pmid">15361840</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.onc.1207966</pub-id>
          </element-citation>
        </ref>
        <ref id="R25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Walsh</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <volume>107</volume>
            <fpage>12629</fpage>
            <lpage>12633</lpage>
            <pub-id pub-id-type="doi">10.1073/pnas.1007983107</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20616022</pub-id>
            <pub-id pub-id-type="pmcid">PMC2906584</pub-id>
          </element-citation>
        </ref>
        <ref id="R26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Prat</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer</article-title>
            <source>Breast Cancer Res</source>
            <volume>12</volume>
            <fpage>R68</fpage>
            <comment>bcr2635 [pii]</comment>
            <pub-id pub-id-type="doi">10.1186/bcr2635</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20813035</pub-id>
            <pub-id pub-id-type="pmcid">PMC3096954</pub-id>
          </element-citation>
        </ref>
        <ref id="R27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kozomara</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Griffiths-Jones</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>miRBase: integrating microRNA annotation and deep-sequencing data</article-title>
            <source>Nucleic Acids Res</source>
            <volume>39</volume>
            <fpage>D152</fpage>
            <lpage>157</lpage>
            <pub-id pub-id-type="doi">10.1093/nar/gkq1027</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21037258</pub-id>
            <pub-id pub-id-type="pmcid">PMC3013655</pub-id>
          </element-citation>
        </ref>
        <ref id="R28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Weigman</surname>
                <given-names>VJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival</article-title>
            <source>Breast Cancer Res Treat</source>
            <pub-id pub-id-type="doi">10.1007/s10549-011-1846-y</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmcid">PMC3387500</pub-id>
            <pub-id pub-id-type="pmid">22048815</pub-id>
          </element-citation>
        </ref>
        <ref id="R29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Curtis</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups</article-title>
            <source>Nature</source>
            <pub-id pub-id-type="doi">10.1038/nature10983</pub-id>
            <year>2012</year>
            <pub-id pub-id-type="pmcid">PMC3440846</pub-id>
            <pub-id pub-id-type="pmid">22522925</pub-id>
          </element-citation>
        </ref>
        <ref id="R30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hennessy</surname>
                <given-names>BT</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers</article-title>
            <source>Clinical proteomics</source>
            <volume>6</volume>
            <fpage>129</fpage>
            <lpage>151</lpage>
            <pub-id pub-id-type="doi">10.1007/s12014-010-9055-y</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">21691416</pub-id>
            <pub-id pub-id-type="pmcid">PMC3116520</pub-id>
          </element-citation>
        </ref>
        <ref id="R31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Daub</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle</article-title>
            <source>Mol Cell</source>
            <volume>31</volume>
            <fpage>438</fpage>
            <lpage>448</lpage>
            <pub-id pub-id-type="doi">10.1016/j.molcel.2008.07.007</pub-id>
            <year>2008</year>
            <pub-id pub-id-type="pmid">18691976</pub-id>
          </element-citation>
        </ref>
        <ref id="R32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Vaske</surname>
                <given-names>CJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Inference of patient-specific pathway activities from multi-dimensional cancer genomics data usingPARADIGM</article-title>
            <source>Bioinformatics</source>
            <volume>26</volume>
            <fpage>i237</fpage>
            <lpage>245</lpage>
            <pub-id pub-id-type="doi">10.1093/bioinformatics/btq182</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20529912</pub-id>
            <pub-id pub-id-type="pmcid">PMC2881367</pub-id>
          </element-citation>
        </ref>
        <ref id="R33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Campbell</surname>
                <given-names>IG</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutation of the PIK3CA gene in ovarian and breast cancer</article-title>
            <source>Cancer Res</source>
            <volume>64</volume>
            <fpage>7678</fpage>
            <lpage>7681</lpage>
            <year>2004</year>
            <pub-id pub-id-type="pmid">15520168</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-04-2933</pub-id>
          </element-citation>
        </ref>
        <ref id="R34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bachman</surname>
                <given-names>KE</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The PIK3CA Gene is Mutated with High Frequency in Human Breast Cancers</article-title>
            <source>Cancer Biol Ther</source>
            <volume>3</volume>
            <fpage>772</fpage>
            <lpage>775</lpage>
            <year>2004</year>
            <pub-id pub-id-type="pmid">15254419</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/cbt.3.8.994</pub-id>
          </element-citation>
        </ref>
        <ref id="R35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Stemke-Hale</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer</article-title>
            <source>Cancer Res</source>
            <volume>68</volume>
            <fpage>6084</fpage>
            <lpage>6091</lpage>
            <year>2008</year>
            <pub-id pub-id-type="pmid">18676830</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-07-6854</pub-id>
            <pub-id pub-id-type="pmcid">PMC2680495</pub-id>
          </element-citation>
        </ref>
        <ref id="R36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Creighton</surname>
                <given-names>CJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer</article-title>
            <source>Breast Cancer Res</source>
            <volume>12</volume>
            <fpage>R40</fpage>
            <pub-id pub-id-type="doi">10.1186/bcr2594</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20569503</pub-id>
            <pub-id pub-id-type="pmcid">PMC2917035</pub-id>
          </element-citation>
        </ref>
        <ref id="R37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Majumder</surname>
                <given-names>PK</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways</article-title>
            <source>Nat Med</source>
            <volume>10</volume>
            <fpage>594</fpage>
            <lpage>601</lpage>
            <pub-id pub-id-type="doi">10.1038/nm1052</pub-id>
            <year>2004</year>
            <pub-id pub-id-type="pmid">15156201</pub-id>
          </element-citation>
        </ref>
        <ref id="R38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Saal</surname>
                <given-names>LH</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair</article-title>
            <source>Nat Genet</source>
            <volume>40</volume>
            <fpage>102</fpage>
            <lpage>107</lpage>
            <year>2008</year>
            <pub-id pub-id-type="pmid">18066063</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2007.39</pub-id>
            <pub-id pub-id-type="pmcid">PMC3018354</pub-id>
          </element-citation>
        </ref>
        <ref id="R39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wagner</surname>
                <given-names>EF</given-names>
              </name>
              <name name-style="western">
                <surname>Nebreda</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Signal integration by JNK and p38 MAPK pathways in cancer development</article-title>
            <source>Nat Rev Cancer</source>
            <volume>9</volume>
            <fpage>537</fpage>
            <lpage>549</lpage>
            <pub-id pub-id-type="doi">10.1038/nrc2694</pub-id>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19629069</pub-id>
          </element-citation>
        </ref>
        <ref id="R40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ciriello</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Cerami</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Sander</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Schultz</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Mutual exclusivity analysis identifies oncogenic network modules</article-title>
            <source>Genome Res</source>
            <volume>22</volume>
            <fpage>398</fpage>
            <lpage>406</lpage>
            <pub-id pub-id-type="doi">10.1101/gr.125567.111</pub-id>
            <year>2012</year>
            <pub-id pub-id-type="pmid">21908773</pub-id>
            <pub-id pub-id-type="pmcid">PMC3266046</pub-id>
          </element-citation>
        </ref>
        <ref id="R41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kannan</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>DNA microarrays identification of primary and secondary target genes regulated by p53</article-title>
            <source>Oncogene</source>
            <volume>20</volume>
            <fpage>2225</fpage>
            <lpage>2234</lpage>
            <year>2001</year>
            <pub-id pub-id-type="pmid">11402317</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.onc.1204319</pub-id>
          </element-citation>
        </ref>
        <ref id="R42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Troester</surname>
                <given-names>MA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Gene expression patterns associated with p53 status in breast cancer</article-title>
            <source>BMC Cancer</source>
            <volume>6</volume>
            <fpage>276</fpage>
            <year>2006</year>
            <pub-id pub-id-type="pmid">17150101</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2407-6-276</pub-id>
            <pub-id pub-id-type="pmcid">PMC1764759</pub-id>
          </element-citation>
        </ref>
        <ref id="R43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Deisenroth</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Thorner</surname>
                <given-names>AR</given-names>
              </name>
              <name name-style="western">
                <surname>Enomoto</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Perou</surname>
                <given-names>CM</given-names>
              </name>
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53</article-title>
            <source>Mol Cell Biol</source>
            <volume>30</volume>
            <fpage>3981</fpage>
            <lpage>3993</lpage>
            <comment>MCB.01284-09 [pii]</comment>
            <pub-id pub-id-type="doi">10.1128/MCB.01284-09</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20547751</pub-id>
            <pub-id pub-id-type="pmcid">PMC2916441</pub-id>
          </element-citation>
        </ref>
        <ref id="R44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pei</surname>
                <given-names>XH</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis</article-title>
            <source>Cancer Cell</source>
            <volume>15</volume>
            <fpage>389</fpage>
            <lpage>401</lpage>
            <comment>S1535-6108(09)00079-8 [pii]</comment>
            <pub-id pub-id-type="doi">10.1016/j.ccr.2009.03.004</pub-id>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19411068</pub-id>
            <pub-id pub-id-type="pmcid">PMC2699569</pub-id>
          </element-citation>
        </ref>
        <ref id="R45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Chicas</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence</article-title>
            <source>Cancer Cell</source>
            <volume>17</volume>
            <fpage>376</fpage>
            <lpage>387</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ccr.2010.01.023</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20385362</pub-id>
            <pub-id pub-id-type="pmcid">PMC2889489</pub-id>
          </element-citation>
        </ref>
        <ref id="R46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Herschkowitz</surname>
                <given-names>JI</given-names>
              </name>
              <name name-style="western">
                <surname>He</surname>
                <given-names>X</given-names>
              </name>
              <name name-style="western">
                <surname>Fan</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Perou</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas</article-title>
            <source>Breast Cancer Res</source>
            <volume>10</volume>
            <fpage>R75</fpage>
            <comment>bcr2142 [pii]</comment>
            <pub-id pub-id-type="doi">10.1186/bcr2142</pub-id>
            <year>2008</year>
            <pub-id pub-id-type="pmid">18782450</pub-id>
            <pub-id pub-id-type="pmcid">PMC2614508</pub-id>
          </element-citation>
        </ref>
        <ref id="R47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lara</surname>
                <given-names>MF</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Gene profiling approaches help to define the specific functions of retinoblastoma family in epidermis</article-title>
            <source>Mol Carcinog</source>
            <volume>47</volume>
            <fpage>209</fpage>
            <lpage>221</lpage>
            <pub-id pub-id-type="doi">10.1002/mc.20376</pub-id>
            <year>2008</year>
            <pub-id pub-id-type="pmid">17932948</pub-id>
          </element-citation>
        </ref>
        <ref id="R48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Baselga</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer</article-title>
            <source>N Engl J Med</source>
            <volume>366</volume>
            <fpage>109</fpage>
            <lpage>119</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa1113216</pub-id>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22149875</pub-id>
            <pub-id pub-id-type="pmcid">PMC5705202</pub-id>
          </element-citation>
        </ref>
        <ref id="R49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jiang</surname>
                <given-names>Z</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status</article-title>
            <source>J Clin Invest</source>
            <comment>41490 [pii]</comment>
            <pub-id pub-id-type="doi">10.1172/JCI41490</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmcid">PMC2929714</pub-id>
            <pub-id pub-id-type="pmid">20679727</pub-id>
          </element-citation>
        </ref>
        <ref id="R50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Chandriani</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response</article-title>
            <source>PLoS One</source>
            <volume>4</volume>
            <fpage>e6693</fpage>
            <pub-id pub-id-type="doi">10.1371/journal.pone.0006693</pub-id>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19690609</pub-id>
            <pub-id pub-id-type="pmcid">PMC2723908</pub-id>
          </element-citation>
        </ref>
        <ref id="R51">
          <label>51</label>
          <element-citation publication-type="journal">
            <collab>The Cancer Genome Atlas Research Network</collab>
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Perou</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Integrated genomic analyses of ovarian carcinoma</article-title>
            <source>Nature</source>
            <volume>474</volume>
            <fpage>609</fpage>
            <lpage>615</lpage>
            <pub-id pub-id-type="doi">10.1038/nature10166</pub-id>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21720365</pub-id>
            <pub-id pub-id-type="pmcid">PMC3163504</pub-id>
          </element-citation>
        </ref>
        <ref id="R52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Audeh</surname>
                <given-names>MW</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Oral poly(ADP-ribose) polymerase inhibitor olaparibin patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial</article-title>
            <source>Lancet</source>
            <volume>376</volume>
            <fpage>245</fpage>
            <lpage>251</lpage>
            <pub-id pub-id-type="doi">10.1016/S0140-6736(10)60893-8</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20609468</pub-id>
          </element-citation>
        </ref>
        <ref id="R53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Fong</surname>
                <given-names>PC</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</article-title>
            <source>N Engl J Med</source>
            <volume>361</volume>
            <fpage>123</fpage>
            <lpage>134</lpage>
            <comment>NEJMoa0900212 [pii]</comment>
            <pub-id pub-id-type="doi">10.1056/NEJMoa0900212</pub-id>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19553641</pub-id>
          </element-citation>
        </ref>
        <ref id="R54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Fedele</surname>
                <given-names>CG</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <volume>107</volume>
            <fpage>22231</fpage>
            <lpage>22236</lpage>
            <pub-id pub-id-type="doi">10.1073/pnas.1015245107</pub-id>
            <year>2010</year>
            <pub-id pub-id-type="pmid">21127264</pub-id>
            <pub-id pub-id-type="pmcid">PMC3009830</pub-id>
          </element-citation>
        </ref>
        <ref id="R55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gewinner</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling</article-title>
            <source>Cancer Cell</source>
            <volume>16</volume>
            <fpage>115</fpage>
            <lpage>125</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ccr.2009.06.006</pub-id>
            <year>2009</year>
            <pub-id pub-id-type="pmid">19647222</pub-id>
            <pub-id pub-id-type="pmcid">PMC2957372</pub-id>
          </element-citation>
        </ref>
      </ref-list>
      <app-group>
        <app id="APP1">
          <title/>
          <sec id="S18">
            <title>Genome Sequencing Centers</title>
            <p id="P37"><italic toggle="yes">Washington University in St. Louis –</italic>Daniel C. Koboldt(<xref ref-type="fn" rid="FN2">1</xref>), Robert S. Fulton(<xref ref-type="fn" rid="FN2">1</xref>), Michael D. McLellan(<xref ref-type="fn" rid="FN2">1</xref>), Heather Schmidt(<xref ref-type="fn" rid="FN2">1</xref>), Joelle Kalicki-Veizer(<xref ref-type="fn" rid="FN2">1</xref>), Joshua F. McMichael(<xref ref-type="fn" rid="FN2">1</xref>), Lucinda L. Fulton(<xref ref-type="fn" rid="FN2">1</xref>), David J. Dooling(<xref ref-type="fn" rid="FN2">1</xref>), Li Ding(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN3">2</xref>), Elaine R. Mardis(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN3">2</xref>,<xref ref-type="fn" rid="FN4">3</xref>), Richard K. Wilson(<xref ref-type="fn" rid="FN2">1</xref>,<xref ref-type="fn" rid="FN3">2</xref>,<xref ref-type="fn" rid="FN4">3</xref>)</p>
          </sec>
          <sec id="S19">
            <title>Genome Characterization Centers</title>
            <p id="P38"><italic toggle="yes">BC Cancer Agency</italic> – Adrian Ally(<xref ref-type="fn" rid="FN5">4</xref>), Miruna Balasundaram(<xref ref-type="fn" rid="FN5">4</xref>), Yaron S.N. Butterfield(<xref ref-type="fn" rid="FN5">4</xref>), Rebecca Carlsen(<xref ref-type="fn" rid="FN5">4</xref>), Candace Carter(<xref ref-type="fn" rid="FN5">4</xref>), Andy Chu(<xref ref-type="fn" rid="FN5">4</xref>), Eric Chuah(<xref ref-type="fn" rid="FN5">4</xref>), Hye-Jung E. Chun(<xref ref-type="fn" rid="FN5">4</xref>), Robin J.N. Coope(<xref ref-type="fn" rid="FN5">4</xref>), Noreen Dhalla(<xref ref-type="fn" rid="FN5">4</xref>), Ranabir Guin(<xref ref-type="fn" rid="FN5">4</xref>), Carrie Hirst(<xref ref-type="fn" rid="FN5">4</xref>), Martin Hirst(<xref ref-type="fn" rid="FN5">4</xref>), Robert A. Holt(<xref ref-type="fn" rid="FN5">4</xref>), Darlene Lee(<xref ref-type="fn" rid="FN5">4</xref>), Haiyan I. Li(<xref ref-type="fn" rid="FN5">4</xref>), Michael Mayo(<xref ref-type="fn" rid="FN5">4</xref>), Richard A. Moore(<xref ref-type="fn" rid="FN5">4</xref>), Andrew J. Mungall(<xref ref-type="fn" rid="FN5">4</xref>), Erin Pleasance(<xref ref-type="fn" rid="FN5">4</xref>), A. Gordon Robertson(<xref ref-type="fn" rid="FN5">4</xref>), Jacqueline E. Schein(<xref ref-type="fn" rid="FN5">4</xref>), Arash Shafiei(<xref ref-type="fn" rid="FN5">4</xref>), Payal Sipahimalani(<xref ref-type="fn" rid="FN5">4</xref>), Jared R. Slobodan(<xref ref-type="fn" rid="FN5">4</xref>), Dominik Stoll(<xref ref-type="fn" rid="FN5">4</xref>), Angela Tam(<xref ref-type="fn" rid="FN5">4</xref>), Nina Thiessen(<xref ref-type="fn" rid="FN5">4</xref>), Richard J. Varhol(<xref ref-type="fn" rid="FN5">4</xref>), Natasja Wye(<xref ref-type="fn" rid="FN5">4</xref>), Thomas Zeng(<xref ref-type="fn" rid="FN5">4</xref>), Yongjun Zhao(<xref ref-type="fn" rid="FN5">4</xref>), Inanc Birol(<xref ref-type="fn" rid="FN5">4</xref>), Steven J.M. Jones(<xref ref-type="fn" rid="FN5">4</xref>), Marco A. Marra(<xref ref-type="fn" rid="FN5">4</xref>), <italic toggle="yes">Broad Institute –</italic> Andrew D. Cherniack(<xref ref-type="fn" rid="FN6">5</xref>), Gordon Saksena(<xref ref-type="fn" rid="FN6">5</xref>), Robert C. Onofrio(<xref ref-type="fn" rid="FN6">5</xref>), Nam H. Pho(<xref ref-type="fn" rid="FN6">5</xref>), Scott L. Carter(<xref ref-type="fn" rid="FN6">5</xref>), Steven E. Schumacher(<xref ref-type="fn" rid="FN6">5</xref>,<xref ref-type="fn" rid="FN7">6</xref>), Barbara Tabak(<xref ref-type="fn" rid="FN6">5</xref>,<xref ref-type="fn" rid="FN7">6</xref>), Bryan Hernandez(<xref ref-type="fn" rid="FN6">5</xref>), Jeff Gentry(<xref ref-type="fn" rid="FN6">5</xref>), Huy Nguyen(<xref ref-type="fn" rid="FN6">5</xref>), Andrew Crenshaw(<xref ref-type="fn" rid="FN6">5</xref>), Kristin Ardlie(<xref ref-type="fn" rid="FN6">5</xref>), Rameen Beroukhim(<xref ref-type="fn" rid="FN6">5</xref>,<xref ref-type="fn" rid="FN8">7</xref>,<xref ref-type="fn" rid="FN9">8</xref>), Wendy Winckler(<xref ref-type="fn" rid="FN6">5</xref>), Gad Getz(<xref ref-type="fn" rid="FN6">5</xref>), Stacey B. Gabriel(<xref ref-type="fn" rid="FN6">5</xref>), Matthew Meyerson(<xref ref-type="fn" rid="FN6">5</xref>,<xref ref-type="fn" rid="FN10">9</xref>,<xref ref-type="fn" rid="FN11">10</xref>), <italic toggle="yes">Brigham and Women’s Hospital and Harvard Medical School</italic>– Lynda Chin(<xref ref-type="fn" rid="FN10">9</xref>,<xref ref-type="fn" rid="FN12">11</xref>), Peter J. Park(<xref ref-type="fn" rid="FN13">12</xref>), and Raju Kucherlapati(<xref ref-type="fn" rid="FN14">13</xref>). <italic toggle="yes">University of North Carolina, Chapel Hill</italic> - Katherine A. Hoadley(<xref ref-type="fn" rid="FN15">14</xref>,<xref ref-type="fn" rid="FN16">15</xref>), J. Todd Auman(<xref ref-type="fn" rid="FN17">16</xref>,<xref ref-type="fn" rid="FN18">17</xref>), Cheng Fan(<xref ref-type="fn" rid="FN16">15</xref>), Yidi J. Turman(<xref ref-type="fn" rid="FN16">15</xref>), Yan Shi(<xref ref-type="fn" rid="FN16">15</xref>), Ling Li(<xref ref-type="fn" rid="FN16">15</xref>), Michael D. Topal(<xref ref-type="fn" rid="FN16">15</xref>,<xref ref-type="fn" rid="FN19">18</xref>), Xiaping He(<xref ref-type="fn" rid="FN15">14</xref>,<xref ref-type="fn" rid="FN16">15</xref>), Hann-Hsiang Chao(<xref ref-type="fn" rid="FN15">14</xref>,<xref ref-type="fn" rid="FN16">15</xref>), Aleix Prat(<xref ref-type="fn" rid="FN15">14</xref>,<xref ref-type="fn" rid="FN16">15</xref>), Grace O. Silva(<xref ref-type="fn" rid="FN15">14</xref>,<xref ref-type="fn" rid="FN16">15</xref>), Michael D. Iglesia(<xref ref-type="fn" rid="FN15">14</xref>,<xref ref-type="fn" rid="FN16">15</xref>), Wei Zhao(<xref ref-type="fn" rid="FN15">14</xref>,<xref ref-type="fn" rid="FN16">15</xref>), Jerry Usary(<xref ref-type="fn" rid="FN16">15</xref>), Jonathan S. Berg(<xref ref-type="fn" rid="FN15">14</xref>,<xref ref-type="fn" rid="FN16">15</xref>), Michael Adams(<xref ref-type="fn" rid="FN15">14</xref>), Jessica Brooker(<xref ref-type="fn" rid="FN19">18</xref>), Junyuan Wu(<xref ref-type="fn" rid="FN16">15</xref>), Anisha Gulabani(<xref ref-type="fn" rid="FN16">15</xref>), Tom Bodenheimer(<xref ref-type="fn" rid="FN16">15</xref>), Alan P. Hoyle(<xref ref-type="fn" rid="FN16">15</xref>), Janae V. Simons(<xref ref-type="fn" rid="FN16">15</xref>), Matthew G. Soloway(<xref ref-type="fn" rid="FN16">15</xref>), Lisle E. Mose(<xref ref-type="fn" rid="FN16">15</xref>), Stuart R. Jefferys(<xref ref-type="fn" rid="FN16">15</xref>), Saianand Balu(<xref ref-type="fn" rid="FN16">15</xref>), Joel S. Parker(<xref ref-type="fn" rid="FN16">15</xref>), D. Neil Hayes(<xref ref-type="fn" rid="FN16">15</xref>,<xref ref-type="fn" rid="FN20">19</xref>), Charles M. Perou(<xref ref-type="fn" rid="FN15">14</xref>,<xref ref-type="fn" rid="FN16">15</xref>,<xref ref-type="fn" rid="FN19">18</xref>), <italic toggle="yes">University of Southern California / Johns Hopkins –</italic> Simeen Malik(<xref ref-type="fn" rid="FN21">20</xref>), Swapna Mahurkar(<xref ref-type="fn" rid="FN21">20</xref>), Hui Shen(<xref ref-type="fn" rid="FN21">20</xref>), Daniel J. Weisenberger(<xref ref-type="fn" rid="FN21">20</xref>), Timothy Triche, Jr.(<xref ref-type="fn" rid="FN21">20</xref>), Phillip H. Lai(<xref ref-type="fn" rid="FN21">20</xref>), Moiz S. Bootwalla(<xref ref-type="fn" rid="FN21">20</xref>), Dennis T. Maglinte(<xref ref-type="fn" rid="FN21">20</xref>), Benjamin P. Berman(<xref ref-type="fn" rid="FN21">20</xref>), David J. Van Den Berg(<xref ref-type="fn" rid="FN21">20</xref>), Stephen B. Baylin(<xref ref-type="fn" rid="FN22">21</xref>), Peter W. Laird(<xref ref-type="fn" rid="FN21">20</xref>)</p>
          </sec>
          <sec id="S20" sec-type="methods">
            <title>Genome Data Analysis</title>
            <p id="P39"><italic toggle="yes">Baylor College of Medicine –</italic>Chad J. Creighton(<xref ref-type="fn" rid="FN23">22</xref>,<xref ref-type="fn" rid="FN24">23</xref>), Lawrence A. Donehower(<xref ref-type="fn" rid="FN23">22</xref>,<xref ref-type="fn" rid="FN24">23</xref>,<xref ref-type="fn" rid="FN25">24</xref>,<xref ref-type="fn" rid="FN26">25</xref>), <italic toggle="yes">Broad Institute</italic> – Gad Getz(<xref ref-type="fn" rid="FN27">26</xref>), Michael Noble(<xref ref-type="fn" rid="FN27">26</xref>), Doug Voet(<xref ref-type="fn" rid="FN27">26</xref>), Gordon Saksena(<xref ref-type="fn" rid="FN27">26</xref>), Nils Gehlenborg(<xref ref-type="fn" rid="FN13">12</xref>,<xref ref-type="fn" rid="FN27">26</xref>), Daniel DiCara(<xref ref-type="fn" rid="FN27">26</xref>), Juinhua Zhang(<xref ref-type="fn" rid="FN28">27</xref>), Hailei Zhang(<xref ref-type="fn" rid="FN27">26</xref>), Chang-Jiun Wu(<xref ref-type="fn" rid="FN29">28</xref>), Spring Yingchun Liu(<xref ref-type="fn" rid="FN27">26</xref>), Michael S. Lawrence(<xref ref-type="fn" rid="FN27">26</xref>), Lihua Zou(<xref ref-type="fn" rid="FN27">26</xref>), Andrey Sivachenko(<xref ref-type="fn" rid="FN27">26</xref>), Pei Lin(<xref ref-type="fn" rid="FN27">26</xref>), Petar Stojanov(<xref ref-type="fn" rid="FN27">26</xref>), Rui Jing(<xref ref-type="fn" rid="FN27">26</xref>), Juok Cho(<xref ref-type="fn" rid="FN27">26</xref>), Raktim Sinha(<xref ref-type="fn" rid="FN27">26</xref>), Richard W. Park(<xref ref-type="fn" rid="FN27">26</xref>), Marc-Danie Nazaire(<xref ref-type="fn" rid="FN27">26</xref>), Jim Robinson(<xref ref-type="fn" rid="FN27">26</xref>), Helga Thorvaldsdottir(<xref ref-type="fn" rid="FN27">26</xref>), Jill Mesirov(<xref ref-type="fn" rid="FN27">26</xref>), Peter J. Park(<xref ref-type="fn" rid="FN13">12</xref>,<xref ref-type="fn" rid="FN30">29</xref>,<xref ref-type="fn" rid="FN31">30</xref>), Lynda Chin(<xref ref-type="fn" rid="FN27">26</xref>,<xref ref-type="fn" rid="FN28">27</xref>), <italic toggle="yes">Institute for Systems Biology</italic> –Sheila Reynolds(<xref ref-type="fn" rid="FN32">31</xref>), Richard B. Kreisberg(<xref ref-type="fn" rid="FN32">31</xref>), Brady Bernard(<xref ref-type="fn" rid="FN32">31</xref>), Ryan Bressler(<xref ref-type="fn" rid="FN32">31</xref>), Timo Erkkila(<xref ref-type="fn" rid="FN33">32</xref>), Jake Lin(<xref ref-type="fn" rid="FN32">31</xref>), Vesteinn Thorsson(<xref ref-type="fn" rid="FN32">31</xref>), Wei Zhang(<xref ref-type="fn" rid="FN34">33</xref>), Ilya Shmulevich(<xref ref-type="fn" rid="FN32">31</xref>), <italic toggle="yes">Memorial Sloan-Kettering Cancer Center</italic> –Giovanni Ciriello(<xref ref-type="fn" rid="FN35">34</xref>), Nils Weinhold(<xref ref-type="fn" rid="FN35">34</xref>), Nikolaus Schultz(<xref ref-type="fn" rid="FN35">34</xref>), Jianjiong Gao(<xref ref-type="fn" rid="FN35">34</xref>), Ethan Cerami(<xref ref-type="fn" rid="FN35">34</xref>), Benjamin Gross(<xref ref-type="fn" rid="FN35">34</xref>), Anders Jacobsen(<xref ref-type="fn" rid="FN35">34</xref>), Rileen Sinha(<xref ref-type="fn" rid="FN35">34</xref>), B. Arman Aksoy(<xref ref-type="fn" rid="FN35">34</xref>), Yevgeniy Antipin(<xref ref-type="fn" rid="FN35">34</xref>), Boris Reva(<xref ref-type="fn" rid="FN35">34</xref>), Ronglai Shen(<xref ref-type="fn" rid="FN36">35</xref>), Barry S. Taylor(<xref ref-type="fn" rid="FN35">34</xref>), Marc Ladanyi(<xref ref-type="fn" rid="FN37">36</xref>), Chris Sander(<xref ref-type="fn" rid="FN35">34</xref>), <italic toggle="yes">Oregon Health and Science University -</italic> Pavana Anur(<xref ref-type="fn" rid="FN38">37</xref>), Paul T.Spellman(<xref ref-type="fn" rid="FN38">37</xref>),<italic toggle="yes">The University of Texas MD Anderson Cancer Center</italic> – Yiling Lu(<xref ref-type="fn" rid="FN39">38</xref>,<xref ref-type="fn" rid="FN40">39</xref>), Wenbin Liu(<xref ref-type="fn" rid="FN41">40</xref>), Roel R.G. Verhaak(<xref ref-type="fn" rid="FN41">40</xref>), Gordon B. Mills(<xref ref-type="fn" rid="FN39">38</xref>,<xref ref-type="fn" rid="FN40">39</xref>), Rehan Akbani(<xref ref-type="fn" rid="FN41">40</xref>), Nianxiang Zhang(<xref ref-type="fn" rid="FN41">40</xref>), Bradley M. Broom(<xref ref-type="fn" rid="FN41">40</xref>), Tod D. Casasent(<xref ref-type="fn" rid="FN41">40</xref>), Chris Wakefield(<xref ref-type="fn" rid="FN41">40</xref>), Anna K. Unruh(<xref ref-type="fn" rid="FN41">40</xref>), Keith Baggerly(<xref ref-type="fn" rid="FN41">40</xref>), Kevin Coombes(<xref ref-type="fn" rid="FN41">40</xref>), John N. Weinstein(<xref ref-type="fn" rid="FN41">40</xref>), <italic toggle="yes">University of California, Santa Cruz / Buck Institute</italic> –David Haussler(<xref ref-type="fn" rid="FN42">41</xref>,<xref ref-type="fn" rid="FN43">42</xref>), Christopher C. Benz(<xref ref-type="fn" rid="FN44">43</xref>), Joshua M. Stuart(<xref ref-type="fn" rid="FN42">41</xref>), Stephen C. Benz(<xref ref-type="fn" rid="FN42">41</xref>), Jingchun Zhu(<xref ref-type="fn" rid="FN42">41</xref>), Christopher C. Szeto(<xref ref-type="fn" rid="FN42">41</xref>), Gary K. Scott(<xref ref-type="fn" rid="FN44">43</xref>), Christina Yau(<xref ref-type="fn" rid="FN44">43</xref>), Evan O. Paull(<xref ref-type="fn" rid="FN42">41</xref>), Daniel Carlin(<xref ref-type="fn" rid="FN42">41</xref>), Christopher Wong(<xref ref-type="fn" rid="FN42">41</xref>), Artem Sokolov(<xref ref-type="fn" rid="FN42">41</xref>), Janita Thusberg(<xref ref-type="fn" rid="FN44">43</xref>), Sean Mooney(<xref ref-type="fn" rid="FN44">43</xref>), Sam Ng(<xref ref-type="fn" rid="FN42">41</xref>), Theodore C. Goldstein(<xref ref-type="fn" rid="FN42">41</xref>), Kyle Ellrott(<xref ref-type="fn" rid="FN42">41</xref>), Mia Grifford(<xref ref-type="fn" rid="FN42">41</xref>), Christopher Wilks(<xref ref-type="fn" rid="FN42">41</xref>), Singer Ma(<xref ref-type="fn" rid="FN42">41</xref>), Brian Craft(<xref ref-type="fn" rid="FN42">41</xref>), <italic toggle="yes">NCI:</italic> Chunhua Yan(<xref ref-type="fn" rid="FN45">44</xref>), Ying Hu(<xref ref-type="fn" rid="FN45">44</xref>), Daoud Meerzaman(<xref ref-type="fn" rid="FN45">44</xref>)</p>
          </sec>
          <sec id="S21">
            <title>Biospecimen Core Resource</title>
            <p id="P40"><italic toggle="yes">Nationwide Children’s Hospital Biospecimen Core Resource –</italic> Julie M. Gastier-Foster(<xref ref-type="fn" rid="FN46">45</xref>,<xref ref-type="fn" rid="FN47">46</xref>,<xref ref-type="fn" rid="FN48">47</xref>), Jay Bowen(<xref ref-type="fn" rid="FN48">47</xref>), Nilsa C. Ramirez(<xref ref-type="fn" rid="FN46">45</xref>,<xref ref-type="fn" rid="FN48">47</xref>), Aaron D. Black(<xref ref-type="fn" rid="FN48">47</xref>), Robert E. Pyatt(<xref ref-type="fn" rid="FN46">45</xref>,<xref ref-type="fn" rid="FN48">47</xref>), Peter White(<xref ref-type="fn" rid="FN47">46</xref>,<xref ref-type="fn" rid="FN48">47</xref>), Erik J. Zmuda(<xref ref-type="fn" rid="FN48">47</xref>), Jessica Frick(<xref ref-type="fn" rid="FN48">47</xref>), Tara M. Lichtenberg(<xref ref-type="fn" rid="FN48">47</xref>), Robin Brookens(<xref ref-type="fn" rid="FN48">47</xref>), Myra M. George(<xref ref-type="fn" rid="FN48">47</xref>), Mark A. Gerken(<xref ref-type="fn" rid="FN48">47</xref>), Hollie A. Harper(<xref ref-type="fn" rid="FN48">47</xref>), Kristen M. Leraas(<xref ref-type="fn" rid="FN48">47</xref>), Lisa J. Wise(<xref ref-type="fn" rid="FN48">47</xref>), Teresa R. Tabler(<xref ref-type="fn" rid="FN48">47</xref>), Cynthia McAllister(<xref ref-type="fn" rid="FN48">47</xref>), Thomas Barr(<xref ref-type="fn" rid="FN48">47</xref>), Melissa Hart-Kothari(<xref ref-type="fn" rid="FN48">47</xref>)</p>
          </sec>
          <sec id="S22">
            <title>Tissue Source Sites</title>
            <p id="P41"><italic toggle="yes">ABS-IUPUI</italic> - Katie Tarvin(<xref ref-type="fn" rid="FN49">48</xref>), Charles Saller(<xref ref-type="fn" rid="FN50">49</xref>), George Sandusky(<xref ref-type="fn" rid="FN51">50</xref>), Colleen Mitchell(<xref ref-type="fn" rid="FN51">50</xref>), <italic toggle="yes">Christiana:</italic> Mary V. Iacocca(<xref ref-type="fn" rid="FN52">51</xref>), Jennifer Brown(<xref ref-type="fn" rid="FN52">51</xref>), Brenda Rabeno(<xref ref-type="fn" rid="FN52">51</xref>), Christine Czerwinski(<xref ref-type="fn" rid="FN52">51</xref>), Nicholas Petrelli(<xref ref-type="fn" rid="FN52">51</xref>), <italic toggle="yes">Cureline –</italic> Oleg Dolzhansky(<xref ref-type="fn" rid="FN53">52</xref>), Mikhail Abramov(<xref ref-type="fn" rid="FN54">53</xref>), Olga Voronina(<xref ref-type="fn" rid="FN55">54</xref>), Olga Potapova(<xref ref-type="fn" rid="FN55">54</xref>), <italic toggle="yes">Duke University Medical Center:</italic> Jeffrey R. Marks(<xref ref-type="fn" rid="FN56">55</xref>), <italic toggle="yes">The Greater Poland Cancer Centre:</italic> Wiktoria M. Suchorska(<xref ref-type="fn" rid="FN57">56</xref>), Dawid Murawa(<xref ref-type="fn" rid="FN57">56</xref>), Witold Kycler(<xref ref-type="fn" rid="FN57">56</xref>), Matthew Ibbs(<xref ref-type="fn" rid="FN57">56</xref>), Konstanty Korski(<xref ref-type="fn" rid="FN57">56</xref>), Arkadiusz Spychała(<xref ref-type="fn" rid="FN57">56</xref>), Paweł Murawa(<xref ref-type="fn" rid="FN57">56</xref>), Jacek J. Brzeziński(<xref ref-type="fn" rid="FN57">56</xref>), Hanna Perz(<xref ref-type="fn" rid="FN57">56</xref>), Radosław ŁaŸniak(<xref ref-type="fn" rid="FN57">56</xref>), Marek Teresiak(<xref ref-type="fn" rid="FN57">56</xref>), Honorata Tatka(<xref ref-type="fn" rid="FN57">56</xref>), Ewa Leporowska(<xref ref-type="fn" rid="FN57">56</xref>), Marta Bogusz-Czerniewicz(<xref ref-type="fn" rid="FN57">56</xref>,<xref ref-type="fn" rid="FN58">57</xref>), Julian Malicki(<xref ref-type="fn" rid="FN57">56</xref>,<xref ref-type="fn" rid="FN58">57</xref>), Andrzej Mackiewicz(<xref ref-type="fn" rid="FN57">56</xref>,<xref ref-type="fn" rid="FN58">57</xref>), Maciej Wiznerowicz(<xref ref-type="fn" rid="FN57">56</xref>,<xref ref-type="fn" rid="FN58">57</xref>), <italic toggle="yes">ILSBio:</italic> Xuan Van Le(<xref ref-type="fn" rid="FN59">58</xref>), Bernard Kohl(<xref ref-type="fn" rid="FN59">58</xref>), Nguyen Viet Tien(<xref ref-type="fn" rid="FN60">59</xref>), Richard Thorp(<xref ref-type="fn" rid="FN61">60</xref>), Nguyen Van Bang(<xref ref-type="fn" rid="FN62">61</xref>), Howard Sussman(<xref ref-type="fn" rid="FN63">62</xref>), Bui Duc Phu(<xref ref-type="fn" rid="FN62">61</xref>), Richard Hajek(<xref ref-type="fn" rid="FN64">63</xref>), Nguyen Phi Hung(<xref ref-type="fn" rid="FN65">64</xref>), Tran Viet The Phuong(<xref ref-type="fn" rid="FN66">65</xref>), Huynh Quyet Thang(<xref ref-type="fn" rid="FN67">66</xref>), Khurram Zaki Khan(<xref ref-type="fn" rid="FN61">60</xref>), <italic toggle="yes">International Genomics Consortium:</italic> Robert Penny(<xref ref-type="fn" rid="FN68">67</xref>), David Mallery(<xref ref-type="fn" rid="FN68">67</xref>), Erin Curley(<xref ref-type="fn" rid="FN68">67</xref>), Candace Shelton(<xref ref-type="fn" rid="FN68">67</xref>), Peggy Yena(<xref ref-type="fn" rid="FN68">67</xref>), <italic toggle="yes">Mayo Clinic:</italic> James N. Ingle(<xref ref-type="fn" rid="FN69">68</xref>), Fergus J. Couch(<xref ref-type="fn" rid="FN69">68</xref>), Wilma L. Lingle(<xref ref-type="fn" rid="FN69">68</xref>), <italic toggle="yes">MSKCC:</italic> Tari A. King(<xref ref-type="fn" rid="FN70">69</xref>), <italic toggle="yes">MD Anderson Cancer Center:</italic> Ana Maria Gonzalez-Angulo(<xref ref-type="fn" rid="FN39">38</xref>,<xref ref-type="fn" rid="FN71">70</xref>), Gordon B. Mills(<xref ref-type="fn" rid="FN71">70</xref>), Mary D. Dyer(<xref ref-type="fn" rid="FN71">70</xref>), Shuying Liu(<xref ref-type="fn" rid="FN71">70</xref>), Xiaolong Meng(<xref ref-type="fn" rid="FN71">70</xref>), Modesto Patangan(<xref ref-type="fn" rid="FN71">70</xref>), <italic toggle="yes">University of California San</italic> Francisco – Frederic Waldman(<xref ref-type="fn" rid="FN72">71</xref>,<xref ref-type="fn" rid="FN73">72</xref>), Hubert Stöppler(<xref ref-type="fn" rid="FN74">73</xref>), <italic toggle="yes">University of North Carolina:</italic> W. Kimryn Rathmell(<xref ref-type="fn" rid="FN16">15</xref>), Leigh Thorne(<xref ref-type="fn" rid="FN16">15</xref>,<xref ref-type="fn" rid="FN75">74</xref>), Mei Huang(<xref ref-type="fn" rid="FN16">15</xref>,<xref ref-type="fn" rid="FN75">74</xref>), Lori Boice(<xref ref-type="fn" rid="FN16">15</xref>,<xref ref-type="fn" rid="FN75">74</xref>), Ashley Hill(<xref ref-type="fn" rid="FN16">15</xref>), <italic toggle="yes">Roswell Park Cancer Institute:</italic> Carl Morrison(<xref ref-type="fn" rid="FN76">75</xref>), Carmelo Gaudioso(<xref ref-type="fn" rid="FN76">75</xref>), Wiam Bshara(<xref ref-type="fn" rid="FN76">75</xref>), <italic toggle="yes">University of Miami</italic> - Kelly Daily(<xref ref-type="fn" rid="FN77">76</xref>), Sophie C. Egea(<xref ref-type="fn" rid="FN77">76</xref>), Marc D. Pegram(<xref ref-type="fn" rid="FN77">76</xref>), Carmen Gomez-Fernandez(<xref ref-type="fn" rid="FN77">76</xref>), <italic toggle="yes">University of Pittsburgh:</italic> Rajiv Dhir(<xref ref-type="fn" rid="FN78">77</xref>), Rohit Bhargava(<xref ref-type="fn" rid="FN79">78</xref>), Adam Brufsky(<xref ref-type="fn" rid="FN79">78</xref>), <italic toggle="yes">Walter Reed National Military Medical Center:</italic> Craig D. Shriver(<xref ref-type="fn" rid="FN80">79</xref>), Jeffrey A. Hooke(<xref ref-type="fn" rid="FN80">79</xref>), Jamie Leigh Campbell(<xref ref-type="fn" rid="FN80">79</xref>), Richard J. Mural(<xref ref-type="fn" rid="FN81">80</xref>), Hai Hu(<xref ref-type="fn" rid="FN81">80</xref>), Stella Somiari(<xref ref-type="fn" rid="FN81">80</xref>), Caroline Larson(<xref ref-type="fn" rid="FN81">80</xref>), Brenda Deyarmin(<xref ref-type="fn" rid="FN81">80</xref>), Leonid Kvecher(<xref ref-type="fn" rid="FN81">80</xref>), Albert J. Kovatich(<xref ref-type="fn" rid="FN82">81</xref>),</p>
          </sec>
          <sec id="S23">
            <title>Disease Working Group</title>
            <p id="P42">Matthew J. Ellis(<xref ref-type="fn" rid="FN4">3</xref>,<xref ref-type="fn" rid="FN83">82</xref>,<xref ref-type="fn" rid="FN84">83</xref>), Tari A. King(<xref ref-type="fn" rid="FN70">69</xref>), Hai Hu(<xref ref-type="fn" rid="FN81">80</xref>), Fergus J. Couch(<xref ref-type="fn" rid="FN69">68</xref>), Richard J. Mural(<xref ref-type="fn" rid="FN81">80</xref>), Thomas Stricker(<xref ref-type="fn" rid="FN85">84</xref>), Kevin White(<xref ref-type="fn" rid="FN85">84</xref>), Olufunmilayo Olopade(<xref ref-type="fn" rid="FN86">85</xref>), James N. Ingle(<xref ref-type="fn" rid="FN69">68</xref>), Chunqing Luo(<xref ref-type="fn" rid="FN81">80</xref>), Yaqin Chen(<xref ref-type="fn" rid="FN81">80</xref>), Jeffrey R. Marks(<xref ref-type="fn" rid="FN56">55</xref>), Frederic Waldman(<xref ref-type="fn" rid="FN72">71</xref>,<xref ref-type="fn" rid="FN73">72</xref>), Maciej Wiznerowicz(<xref ref-type="fn" rid="FN57">56</xref>,<xref ref-type="fn" rid="FN58">57</xref>), Ron Bose(<xref ref-type="fn" rid="FN4">3</xref>,<xref ref-type="fn" rid="FN83">82</xref>,<xref ref-type="fn" rid="FN84">83</xref>), Li-Wei Chang(<xref ref-type="fn" rid="FN87">86</xref>), Andrew H. Beck(<xref ref-type="fn" rid="FN11">10</xref>), Ana Maria Gonzalez-Angulo(<xref ref-type="fn" rid="FN39">38</xref>,<xref ref-type="fn" rid="FN71">70</xref>)</p>
          </sec>
          <sec id="S24" sec-type="methods">
            <title>Data Coordination Center</title>
            <p id="P43">Todd Pihl(<xref ref-type="fn" rid="FN88">87</xref>), Mark Jensen(<xref ref-type="fn" rid="FN88">87</xref>), Robert Sfeir(<xref ref-type="fn" rid="FN88">87</xref>), Ari Kahn(<xref ref-type="fn" rid="FN88">87</xref>), Anna Chu(<xref ref-type="fn" rid="FN88">87</xref>), Prachi Kothiyal(<xref ref-type="fn" rid="FN88">87</xref>), Zhining Wang(<xref ref-type="fn" rid="FN88">87</xref>), Eric Snyder(<xref ref-type="fn" rid="FN88">87</xref>), Joan Pontius(<xref ref-type="fn" rid="FN88">87</xref>), Brenda Ayala(<xref ref-type="fn" rid="FN88">87</xref>), Mark Backus(<xref ref-type="fn" rid="FN88">87</xref>), Jessica Walton(<xref ref-type="fn" rid="FN88">87</xref>), Julien Baboud(<xref ref-type="fn" rid="FN88">87</xref>), Dominique Berton(<xref ref-type="fn" rid="FN88">87</xref>), Matthew Nicholls(<xref ref-type="fn" rid="FN88">87</xref>), Deepak Srinivasan(<xref ref-type="fn" rid="FN88">87</xref>), Rohini Raman(<xref ref-type="fn" rid="FN88">87</xref>), Stanley Girshik(<xref ref-type="fn" rid="FN88">87</xref>), Peter Kigonya(<xref ref-type="fn" rid="FN88">87</xref>), Shelley Alonso(<xref ref-type="fn" rid="FN88">87</xref>), Rashmi Sanbhadti(<xref ref-type="fn" rid="FN88">87</xref>), Sean Barletta(<xref ref-type="fn" rid="FN88">87</xref>), David Pot(<xref ref-type="fn" rid="FN88">87</xref>)</p>
          </sec>
          <sec id="S25">
            <title>Project Team</title>
            <p id="P44"><italic toggle="yes">National Cancer Institute:</italic> Margi Sheth(<xref ref-type="fn" rid="FN89">88</xref>), John A. Demchok(<xref ref-type="fn" rid="FN89">88</xref>), Kenna R Mills Shaw(<xref ref-type="fn" rid="FN89">88</xref>), Liming Yang(<xref ref-type="fn" rid="FN89">88</xref>), Greg Eley(<xref ref-type="fn" rid="FN90">89</xref>), Martin L. Ferguson(<xref ref-type="fn" rid="FN91">90</xref>), Roy W. Tarnuzzer(<xref ref-type="fn" rid="FN89">88</xref>), Jiashan Zhang(<xref ref-type="fn" rid="FN89">88</xref>), Laura A. L. Dillon(<xref ref-type="fn" rid="FN89">88</xref>), Kenneth Buetow(<xref ref-type="fn" rid="FN45">44</xref>), Peter Fielding (<xref ref-type="fn" rid="FN89">88</xref>) <italic toggle="yes">National Human Genome Research Institute</italic>: Bradley A. Ozenberger(<xref ref-type="fn" rid="FN92">91</xref>), Mark S. Guyer(<xref ref-type="fn" rid="FN92">91</xref>), Heidi J. Sofia(<xref ref-type="fn" rid="FN92">91</xref>), Jacqueline D. Palchik(<xref ref-type="fn" rid="FN92">91</xref>)</p>
          </sec>
        </app>
      </app-group>
    </back>
    <floats-group>
      <fig id="F1" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <title>Significantly Mutated Genes (SMG) and correlations with genomic and clinical features</title>
          <p>Tumor samples are grouped by mRNA-subtype: Luminal A (n=225), Luminal B (n=126), HER2E (n=57), and Basal-like (n=93). <bold>Left</bold>: Non-silent somatic mutation patterns and frequencies for SMGs. <bold>Middle</bold>: Clinical features: black, positive or T2-4; white, negative or T1; grey, NA or equivocal. <bold>Right</bold>: SMGs with frequent copy number amplifications (red) or deletions (blue). <bold>Far Right</bold>: Non-silent mutation rate per tumor (mutations per megabase, adjusted for coverage). Average mutation rate for each expression subtype is indicated. Hypermutated: mutation rates &gt; 3 SD above the mean (&gt; 4.688, indicated by grey line).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms393293f1.jpg"/>
      </fig>
      <fig id="F2" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <title>Coordinated analysis of breast cancer subtypes defined from five different genomic/proteomic platforms</title>
          <p>a) Consensus clustering analysis of the subtypes identifies four major groups (samples, n=348). The blue and white heatmap displays sample consensus. b) Heatmap display of the subtypes defined independently by microRNAs, DNA methylation, copy number, PAM50 mRNA expression, and RPPA expression. Red bar indicates membership of a cluster type. c) Associations with molecular and clinical features. P-values were calculated using a Chi-square test.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms393293f2.jpg"/>
      </fig>
      <fig id="F3" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <title>Integrated analysis of the PI3K, TP53, and RB1 pathways</title>
          <p>Breast cancer subtypes differ by genetic and genomic targeting events, with corresponding effects on pathway activity. For a) PI3K, b) TP53 and c) RB1 pathways, key genes were selected using prior biological knowledge. Multiple mRNA expression signatures for a given pathway were defined (details in <xref rid="SD1" ref-type="supplementary-material">Supplemental Methods</xref>; <italic toggle="yes">PI3K:Saal</italic>, PTEN loss in human breast tumors; <italic toggle="yes">PI3K:CMap</italic>, PI3K/mTOR inhibitor treatment <italic toggle="yes">in vitro; PI3K:Majumder</italic>, Akt over-expression in mouse model; <italic toggle="yes">p53:IARC</italic>, expert-curated p53 targets; <italic toggle="yes">p53:GSK</italic>, <italic toggle="yes">TP53</italic> mutant versus wild-type cell lines; <italic toggle="yes">p53:KANNAN</italic>, p53 over-expression <italic toggle="yes">in vitro; p53:TROESTER</italic>, <italic toggle="yes">TP53</italic> knockdown <italic toggle="yes">in vitro; Rb:CHICAS</italic>, <italic toggle="yes">RB1</italic> mouse knockout versus wild-type; <italic toggle="yes">Rb:LARA</italic>, <italic toggle="yes">RB1</italic> knockdown <italic toggle="yes">in vitro; Rb:HERSCHKOWITZ</italic>, <italic toggle="yes">RB1</italic> LOH in human breast tumors) and applied to the gene expression data, in order to score each tumor for relative signature activity (yellow: more active). The PI3K panel includes a protein-based (RPPA) proteomic signature. Tumors were ordered first by mRNA-subtype, though specific ordering differs between the panels. P-values were calculated by a Pearson’s correlation or a Chi-squared test.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms393293f3.jpg"/>
      </fig>
      <fig id="F4" orientation="portrait" position="float">
        <label>Figure 4</label>
        <caption>
          <title>Mutual Exclusivity Modules in Cancer (MEMo) analysis</title>
          <p>Mutual exclusivity modules are represented by their gene components and connected to reflect their activity in distinct pathways. For each gene, the frequency of alteration in Basal-like (right box) and non-Basal (left box) is reported. Next to each module is a fingerprint indicating what specific alteration is observed for each gene (row) in each sample (column). a) MEMo identified several overlapping modules that recapitulate the RTK/PI3K and p38/JNK1 signaling pathways and whose core was the top-scoring module. b) MEMo identified alterations to TP53 signaling as occurring within a statistically significant mutually exclusive trend. c) A Basal-like only MEMo analysis identified one module that included ATM mutations, defects at BRCA1 and BRCA2, and deregulation of the RB1-pathway. A gene expression heatmap is below the fingerprint to show expression levels.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms393293f4.jpg"/>
      </fig>
      <fig id="F5" orientation="portrait" position="float">
        <label>Figure 5</label>
        <caption>
          <title>Comparison of Breast and Serous Ovarian carcinomas</title>
          <p>a) Significantly enriched genomic alterations identified by comparing Basal-like or Serous Ovarian tumors to Luminal cancers. b) Inter-sample correlations (yellow: positive) between gene transcription profiles of breast tumors (columns; TCGA data, arranged by subtype) and profiles of cancers from various tissues of origin (rows; external “TGEN expO” dataset, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE2109">GSE2109</ext-link>) including Ovarian cancers.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms393293f5.jpg"/>
      </fig>
      <table-wrap id="T1" position="float" orientation="portrait">
        <label>Table 1</label>
        <caption>
          <p>Summary of disease subtypes findings highlighting some of the dominant genomic, clinical, and proteomic features.</p>
        </caption>
        <table frame="box" rules="all">
          <thead>
            <tr>
              <th valign="middle" align="left" rowspan="1" colspan="1"/>
              <th valign="middle" align="left" rowspan="1" colspan="1">Luminal A</th>
              <th valign="middle" align="left" rowspan="1" colspan="1">Luminal B</th>
              <th valign="middle" align="left" rowspan="1" colspan="1">Basal-like</th>
              <th valign="middle" align="left" rowspan="1" colspan="1">HER2E</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">% ER+/HER2−</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">87%</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">82%</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">10%</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">20%</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">% HER2+</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">7%</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">15%</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">2%</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">68%</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">% TNBC</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">2%</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">1%</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">80%</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">9%</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">p53 Pathway</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">TP53 mut (12%)<break/>Gain of MDM2 (14%)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">TP53 mut (32%)<break/>Gain of MDM2 (31%)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">TP53 mut (84%)<break/>Gain of MDM2 (14%)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">TP53 mut (75%)<break/>Gain of MDM2 (30%)</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">PIK3CA/PTEN Pathway</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">PIK3CA mut (49%)<break/>PTEN mut/loss (13%)<break/>INPP4B loss (9%)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">PIK3CA mut (32%)<break/>PTEN mut/loss (24%)<break/>INPP4B loss (16%)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">PIK3CA mut (7%)<break/>PTEN mut/loss (35%)<break/>INPP4B loss (30%)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">PIK3CA mut (42%)<break/>PTEN mut/loss (19%)<break/>INPP4B loss (30%)</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">RB1 Pathway</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Cyclin D1 amp (29%)<break/>CDK4 gain (14%)<break/>Low expression of CDKN2C<break/>High expression of RB1</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Cyclin D1 amp (58%)<break/>CDK4 gain (25%)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">RB1 mut/loss (20%)<break/>Cyclin E1 amp (9%)<break/>High expression of CDKN2A<break/>Low expression of RB1</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Cyclin D1 amp (38%)<break/>CDK4 gain (24%)</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">mRNA Expression</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">High ER cluster<break/>Low proliferation</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Lower ER cluster<break/>High proliferation</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Basal signature<break/>High proliferation</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">HER2 amplicon signature<break/>High proliferation</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Copy Number</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Most diploid<break/>Many with quiet genomes<break/>1q, 8q, 8p11 gain<break/>8p, 16q loss<break/>11q13.3 amp (24%)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Most aneuploid<break/>Many with focal amps<break/>1q, 8q, 8p11 gain<break/>8p, 16q loss<break/>11q13.3 amp (51%)<break/>8p11.23 amp (28%)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Most aneuploid<break/>High genomic instability<break/>1q, 10p gain<break/>8p, 5q loss<break/>MYC focal gain (40%)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Most aneuploid<break/>High genomic instability<break/>1q, 8q gain<break/>8p loss<break/>17q12 focal ERRB2 amp (71%)</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">DNA Mutations</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">PIK3CA (49%)<break/>TP53 (12%)<break/>GATA3 (14%)<break/>MAP3K1 (14%)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">TP53 (32%)<break/>PIK3CA (32%)<break/>MAP3K1 (5%)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">TP53 (84%)<break/>PIK3CA (7%)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">TP53 (75%)<break/>PIK3CA (42%)<break/>PIK3R1 (8%)</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">DNA Methylation</td>
              <td align="left" valign="middle" rowspan="1" colspan="1"/>
              <td align="left" valign="middle" rowspan="1" colspan="1">Hyper-methylated phenotype for subset</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Hypo-methylated</td>
              <td align="left" valign="middle" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Protein Expression</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">High Estrogen-signaling<break/>High cMYB<break/>RPPA reactive subtypes</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Less Estrogen-signaling<break/>High FOXM1 and cMYC<break/>RPPA reactive subtypes</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">High expression of DNA repair proteins, PTEN and INPP4B loss signature (p-AKT)</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">High protein and phos-protein expression of HER1 and HER2</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN1">
            <p>Percentages are based on 466 tumor overlap list</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </floats-group>
  </article>
</pmc-articleset>
